 
 
 
CONNECTS Master Protocol for Clinical Trials targeting macro -, micro -immuno -
thrombosis, vascular hyperinflammation, and hypercoagulability and renin -angiotensin -
aldosterone system (RAAS) in hospi[INVESTIGATOR_41374] -19 (ACTIV -[ADDRESS_227664] Tissue ) 
 
 
Short Title:  Novel Experimental COVID Therap ies Affecting Host Response (NECTAR)  
 
COVID -[ADDRESS_227665] Tissue Master Protocol  
 
ClinicalTrials.gov Number:  [STUDY_ID_REMOVED]  
 
Supported by: [CONTACT_74379] -CONNECTS  
 
Version Number: 5.0 
 
2023.08.07  
 
  Study Chair  
 
 
Principal Investigator,  
Clinical Coordinating Center  
 Sean P. Collins, MD, MSc  
Email: [EMAIL_3788]   
 
Wesley H. Self, MD, MPH  
Email: [EMAIL_3789]   
Principal Investigator,  
Data Coordinating Center   Matthew S. Shotwell, PhD  
Email: [EMAIL_3790]    
Trial Biostatisticians  Christopher J. Lindsell , PhD  
Email: [EMAIL_1777]    
 
James Troendle , PhD  
NHLBI  
Email: [EMAIL_3791]   
Medical Monitor  Matthew Semler, MD , MSc  
Email: [EMAIL_3792]   
NHLBI Representative  Yves Rosenberg , MD  
Email: [EMAIL_3793]   
Ex-U.S. Sponsor  NEAT -ID 
IND 154000  
ClinicalTrials.gov Identifier  [STUDY_ID_REMOVED]  
NECTAR EudraCT  [ADDRESS_227666](s) to COVID -19................................ ...................... [ADDRESS_227667] tissue therapi[INVESTIGATOR_14953] a single platform among patients who 
are hospi[INVESTIGATOR_21391] -19 ................................ ................................ ............................. 12 
3.4 Potential Risks & Benefits  ................................ ................................ ........................... 13 
4 Study Objectives and Purpose  ................................ ................................ ........................... 13 
4.1 Study Objectives  ................................ ................................ ................................ ......... 14 
4.2 Study Hypothesis  ................................ ................................ ................................ ........ 14 
5 Study Design and Outcomes ................................ ................................ .............................. 14 
5.1 Overall Study Design  ................................ ................................ ................................ ..14 
5.2 Randomization  ................................ ................................ ................................ ............ 14 
5.3 Study Outcomes  ................................ ................................ ................................ ......... 14 
5.3.1  Primary Study  Outcome  ................................ ................................ ....................... 14 
5.3.2  Secondary Outcomes  ................................ ................................ .......................... 15 
5.3.3  Exploratory Outcomes  ................................ ................................ ......................... 16 
5.3.4  Safety Outcomes (systematically collected during index hospi[INVESTIGATOR_059])  .............. 16 
6 Study population and enrollment  ................................ ................................ ........................ 16 
6.1 Inclusion criteria  ................................ ................................ ................................ .......... 16 
6.2 Exclusion criteria  ................................ ................................ ................................ ......... 17 
6.3 Justification of exclusion criteria  ................................ ................................ .................. 17 
6.4 Special screening procedures  ................................ ................................ ..................... 18 
6.5 Assessment of eligibility and exclusion tracking  ................................ .......................... 18 
6.6 Process of obtaining informed consent  ................................ ................................ .......18 
6.6.1  Paper -based approach  ................................ ................................ ........................ 18 
6.6.2  Electronic/e -consent approach for US sites only  ................................ .................. [ADDRESS_227668] udy Participation  ................................ ................................ .................... 22 
6.11  Participant Withdrawal or Termination  ................................ ................................ ......... 22 
6.11.1  Reasons for Withdrawal or Termination  ................................ ............................... 22 
6.11.2  Premature Termination or Suspension  ................................ ................................ .22 
7 Study Procedures and Schedule  ................................ ................................ ........................ 23 
7.1 Study interventions  ................................ ................................ ................................ .....23 
7.2 Expedited Critical and Major Event Reporting  ................................ ............................. 23 
7.3 Data and Safety Monitoring Plan  ................................ ................................ ................. 23 
7.4 Biological specimens  ................................ ................................ ................................ ..24 
7.5 Shared placebo group dose, duration, and route of administration  .............................. 24 
7.6 Co-Interventions and Co -enrollment  ................................ ................................ ........... 24 
7.7 On study monitoring  ................................ ................................ ................................ ....25 
7.7.1  Laboratory evaluations  ................................ ................................ ......................... 25 
7.7.2  Clinical evaluations  ................................ ................................ .............................. 25 
7.7.3  Criteria for stoppi[INVESTIGATOR_21395]  ................................ ................................ ..................... 25 
7.7.4  Plan for drug shortages  ................................ ................................ ........................ 26 
7.7.5  Baseline variable collection  ................................ ................................ .................. 26 
7.7.6  Assessments between hospi[INVESTIGATOR_191540]  ................... 27 
7.7.7  Assessments following hospi[INVESTIGATOR_2345]  ................................ ........................... 27 
8 Statistical Considerations  ................................ ................................ ................................ ...29 
8.1 Statistical and Analytical Plans ................................ ................................ .................... 29 
8.2 Analysis Datasets  ................................ ................................ ................................ .......29 
8.3 Statistical Modeling  ................................ ................................ ................................ .....29 
8.4 Loss to Follow -up, Censoring, and Intercurrent Events  ................................ ............... 30 
8.5 Model Prior and Bayesian Computation  ................................ ................................ ......30 
8.6 Analysis of Primary Outcome  ................................ ................................ ...................... 30 
8.6.1  Primary Analysis  ................................ ................................ ................................ ..30 
8.6.2  Planned Interim and Final Analyses, Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  ....31 
8.6.3  Supplementary Efficacy Estimands  ................................ ................................ ......31 
8.6.4  Sensitivity and Supplementary Analyses  ................................ .............................. 31 
8.6.5  Sample Size and Decision Thresholds  ................................ ................................ .33 
8.7 Analysis of Secondary Outcomes  ................................ ................................ ............... 35 
8.8 Analysis of Safety Outcomes  ................................ ................................ ...................... 36 
8.9 Adherence and Retention Analyses  ................................ ................................ ............ 36 
8.10  Baseline Descriptive Statistics  ................................ ................................ .................... 36 
8.11  Exploratory Analyses  ................................ ................................ ................................ ..36 
9 Measures to Minimize Bias  ................................ ................................ ................................ 36 
9.1 Enrollment/Randomization/Blinding  ................................ ................................ ............ 36 
10 Source Documents and Access to Source Data/Documents  ................................ .............. 36 
11 Quality Assurance and Quality Control  ................................ ................................ ............... 37 
12 Ethics/Protection of Human Subjects  ................................ ................................ ................. [ADDRESS_227669]  ................................ ................................ ................................ ......... 37 
12.2  IRB/Ethics Committee/Competent Authority  ................................ ................................ 37 
12.3  Posting of Clinical Trial Consent Form  ................................ ................................ ........ 37 
12.4  Participant and Data Confidentiality  ................................ ................................ ............ 37 
12.5  Certificate of Confidentiality  ................................ ................................ ........................ 38 
13 Adverse events  ................................ ................................ ................................ .................. 38 
13.1  Defining adverse events  ................................ ................................ ............................. 40 
13.2  Protocol -specified exempt serious events (PSESEs)  ................................ .................. [ADDRESS_227670] (DSMB)  ................................ ................................ ........ [ADDRESS_227671] locking  ................................ ................................ ................................ .....49 
16.4.2  eConsent  ................................ ................................ ................................ ............. 49 
17 End of Trial  ................................ ................................ ................................ ........................ 50 
18 Study Finances  ................................ ................................ ................................ .................. 50 
18.1  Funding Source  ................................ ................................ ................................ .......... 50 
18.2  Costs to the Participant  ................................ ................................ ............................... 50 
19 Appendix A: Primary study outcomes  ................................ ................................ ................. 51 
19.1  Approach to ascertainment and verification of outcomes  ................................ ............ 51 
19.2  Primary outcome: Oxygen free days  ................................ ................................ ........... 51 
19.3  Definitions  ................................ ................................ ................................ ................... 53 
19.3.1  ICU Level of care  ................................ ................................ ................................ .53 
19.3.2  Myocardial injury  ................................ ................................ ................................ ..53 
19.3.3  Acute Kidney Injury  ................................ ................................ .............................. 53 
19.3.4  Disseminated Intravascular Coagulation (DIC) (Overt) – DIC score ≥ 5  ............... 53 
19.3.5  ISTH Defined Major Bleeding  ................................ ................................ ............... 54 
20 Appendix B: Data and Safety Monitoring Plan  ................................ ................................ ....55 
20.1  Overview  ................................ ................................ ................................ ..................... 55 
21 Appendix C: Minimum Biological Specimen collection  ................................ ....................... 56 
22 Appendix D: Arm 3: Fostamatinib  ................................ ................................ ....................... [ADDRESS_227672] of Tables  
Table 1.  Schedule of Events  ................................ ................................ ................................ .28 
Table 2.  Overview of Safety Data Collection  ................................ ................................ ......... 39 
Table 3.  WHO COVID -19 Clinical Status Scale and its use for enrollment eligibility and   
 calculation of oxygen free days (OFD)  ................................ ................................ .....[ADDRESS_227673] of Figures  
Figure 1.  Physiological steps of the generation of angiotensin II and angiotensin 1 -7 and 
their actions on specific receptors  ................................ ................................ ............................. 13 
Figure 2.  Adverse Event and Clinical Outcome Assessment, Recording, and Reporting  .....46 
Figure 3.  Spleen tyrosine kinase inhibition in COVID -19 (Strich, Generated using    
 Biorender)  …… ................................ ................................ ................................ ....[ADDRESS_227674] of Abbreviations  
 
AE Adverse Event/Adverse Experience  
AESI  Adverse Event of Special Interest  
ARDS  Acute Respi[INVESTIGATOR_191541] -[ADDRESS_227675]  End-stage renal disease  
FDA Food and Drug Administration  
FFR Federal Financial Report  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulations  
GI Gastrointestinal  
HFNO  High-flow Nasal Oxygen (≥30L/min)  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ISTH  International Society on Thrombosis and Hemostasis  
ITT Intent to Treat  
LAR Legally Authorized Representative  
LOS Length of Stay  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NETs  Neutrophil extracellular traps  
NIH National Institutes of Health  
NIV Non-Invasive Ventilation  
NYULH  [LOCATION_001] University Langone Health  
OFD  Oxygen Free Days  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Participants Research  
OSFD  Organ Support Free Days  
PI [INVESTIGATOR_191542] -specified exempt serious events  
PTT Partial Thromboplastin Time  
QA Quality Assurance  
QC Quality Control  
RRT Renal Replacement Therapy  
SARS -CoV-2 Severe Acute Respi[INVESTIGATOR_23223] - Coronavirus - 2  
SAE Serious Adverse Event/Serious Adverse Experience  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
SOP  Standard Operating Procedure  
US [LOCATION_002]  
VTE Venous Thromboembolism  
WHO  World Health Organization  
WOCBP  Women of Childbearing Potential  
  
Study number : [ADDRESS_227676] Tissue  
Protocol Version: 5.[ADDRESS_227677] tissue and the renin -
angiotensin -aldosterone system (RAAS) in hospi[INVESTIGATOR_41374] -
[ADDRESS_227678]  Response  (NECTAR)  
Brief Summary  This Master Protocol describes the general design features of a platform trial 
evaluating therapi[INVESTIGATOR_191543] -19 in hospi[INVESTIGATOR_138592]. The Master Protocol provides the background and overarching 
approach to all trials to be conducted on this platform . This includes a 
rationale for the choice of primary outcome , inclusion an d exclusion criteria, 
randomization and blinding, interim and final analyses, sample size 
considerations, safety  reporting,  and data collection.  In addition, the Master 
Protocol describes general principles for trial operations and oversight. 
Appendices to  the Master Protocol provide agent -specific details, including 
treatment dose, route and frequency, safety information, and any agent - 
specific considerations related to drug starting/stoppi[INVESTIGATOR_007], inclusion and 
exclusion criteria and blinding procedures.  
Objectives  The overarching goal of the Master Protocol is to find effective strategies for 
inpatient management of patients with COVID -19. Therapeutic goals for 
patients hospi[INVESTIGATOR_191544] -[ADDRESS_227679] tissue response 
improves clinical outcomes among patients with COVID -19. 
 
Potential agent (s) to investigate on this platform include , but are not limited 
to, TXA127 , TRV027 , and Fostamatinib . These agents all impact the host 
tissue response in COVID -19 via a number of unique mechanisms including  
potential beneficial effects on the RAAS system  and formation of neutrophil 
extracellular traps  (NETs) .  We will evaluate the efficacy of these agents’ 
ability to impact the host tissue response and improve outcomes in patients 
hospi[INVESTIGATOR_21391] -19.  
Methodology  This platform will be a randomized, placebo -controlled trial of agents  
targeting the host response in COVID -19 in hospi[INVESTIGATOR_9643] . The Master 
Protocol is designed to be flexible in the number of study arms, the use of a 
single placebo  group, and the stoppi[INVESTIGATOR_191545].  
Study number : [ADDRESS_227680] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Outcomes  Primary Outcome:   
Oxygen free days through  day 28. This is defined as days alive and without 
supplemental oxygen use during the first 28 days following randomization. 
Patients who die prior to day 28 are assigned  -1 oxygen  free days.   
 
Secondary outcomes:  
• In hospi[INVESTIGATOR_34380]  
• Proportion of patients alive and oxygen free at days 14 and 28  
• Proportion of patients with new invasive mechanical ventilation at day 28  
• 28-day mortality  
• 60-day mortality  
• 90-day mortality    
• WHO 8 -point ordinal scale at 14 , 28, and 60 days  
▪ 1: Ambulatory – Not hospi[INVESTIGATOR_82800] n o limitation of activities  
▪ 2: Ambulatory – Not hospi[INVESTIGATOR_191546] l imitation of activities  or 
home oxygen use  
▪ 3: Hospi[INVESTIGATOR_191547] – Hospi[INVESTIGATOR_057], no oxygen 
therapy  
▪ 4: Hospi[INVESTIGATOR_191547] – Hospi[INVESTIGATOR_057], oxygen by [CONTACT_191632]  
▪ 5: Hospi[INVESTIGATOR_191548] – Non-invasive ventilation o r 
high-flow nasal cannula  
▪ 6: Hospi[INVESTIGATOR_191548] –Invasive mechanical 
ventilation  
▪ 7: Hospi[INVESTIGATOR_191548] – Invasive mechanical 
ventilation plus additional organ support with - vasopressors, 
RRT, or ECMO  
▪ 8: Dead  
• Support -free days through  Day 28, including:  
o Hospi[INVESTIGATOR_307] -free days  
o Ventilator -free days  
o Respi[INVESTIGATOR_191549]  
• Renal outcomes: acute kidney Injury defined as > KDIGO Stage 2 and 
changes in serum creatinine and estimated Glomerular Filtration Rate  
• Myocardial injury as measured by [CONTACT_191633], during and 
after therapy during hospi[INVESTIGATOR_059] (when possible, at participating U.S. 
sites)   
• RAAS pathway m echanistic biomarkers (AngII, Ang(1 -7), ACE and A CE2) 
(when possible  and applicable , at participating U.S. sites)  
• Trajectories of biomarkers related to COVID -19 (when possible, at 
participating U.S. sites)  
• Changes in NT -proBNP  before, during and after therapy during 
hospi[INVESTIGATOR_059] (when possible, at participating U.S. sites) 
 
 
 
Study number : [ADDRESS_227681] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Safety outcomes (systematically collected during index 
hospi[INVESTIGATOR_059]):  
• Hypotension as defined by [CONTACT_191634] [1 ] 
initiation or increase in vasopressor therapy, [2] administration of a fluid 
bolus of 500 ml or more, or [3] modification of the dose or discontinuation 
of the study drug.  
• Allergic reaction, including angioedema  and rash  
• Incident renal replacement therap y during hospi[INVESTIGATOR_191550] [ADDRESS_227682] -discharge follow -up for up to 90 days 
after randomization.  (Specific eligibility criteria are in the main protocol text)  
Population  Patients hospi[INVESTIGATOR_191544] -[ADDRESS_227683] interim analysis , sample size adequacy  was re-assessed 
based on the poole d (across all active and placebo arms)  distribution  of the 
primary outcome . No adjustments to t he maximum sample size were  made.  
Placebo enrollment beyond [ADDRESS_227684] tissue response to COVID -
19. 
Key 
Procedures  Participants will be recruited in the inpatient setting. They will undergo 
baseline evaluations for eligibility. They will then be randomized, stratified by 
[CONTACT_3725], and study intervention will begin. Baseline laboratories will be required, 
and biobanking will occur both at randomization , and during the study period. 
The primary outcome will be assessed daily via chart review during 
hospi[INVESTIGATOR_059]. Patients will undergo additional data collection by [CONTACT_756], 
mail, in-person visits or electronic (e.g ., email, text message) survey s after 
discharge.  
Study number : [ADDRESS_227685] Tissue  
Protocol Version: 5.[ADDRESS_227686] of each study agent on the primary outcome, versus matching 
placebo, will be quantified using the odds ratio to evaluate the odds of  
greate r oxygen  free days at day 28 (i.e., the primary estimand). Estimation 
and inferences about the primary estimand will be made using proportional 
odds logistic regression methods. For each study agent, the comparison  
group will consist of all concurrently ra ndomized placebo participants 
meet ing the inclusion and exclusion criteria for that agent.  
For each arm, we will use pre -planned interim analyses at fixed recruitment 
intervals to consider ending enrollment early due to strong evidence of 
inferiority . Early stoppi[INVESTIGATOR_191551] a type -I error probability of 2.5 % (one-sided) , separately for each 
study agent.  
We will use a modified intention to treat ( mITT) approach for primary 
analyses. All available data  on participants who were eligible, randomized , 
and received at least some study drug  will be used to compare each 
treatment versus control, regardless of post -randomization adherence to 
study protocols. The intercurrent event of death will b e coded as a special 
value in the primary outcome (i.e ., composite strategy). Censoring in the 
primary outcome will be modeled using likelihood methods. No other 
intercurrent events will affect the primary outcome (i.e., treatment policy 
strategy).  We will monitor closely for patients who are randomized who do 
not receive study drug to ensure our preplanned sample size targets for the 
mITT group are met.            
 
3 Introduction, Background Information and Scientific Rationale  
3.1 Background Informatio n, Significance and Relevant Literature  
The severe acute respi[INVESTIGATOR_6507] 2  (SARS -CoV-2), which causes  coronavirus 
disease 2019 (COVID -19), has resulted in a global pandemic. The clinical spectrum of COVID -[ADDRESS_227687] illness, and 
severe viral pneumonia with respi[INVESTIGATOR_42679].  Between 13 and 40 % of patients become 
hospi[INVESTIGATOR_057],1,2 up to 3 0% of those hospit alized requir e admission for intensive care , and there is  a 
13% inpatient mortality rate .3,4 The reasons for hospi[INVESTIGATOR_191552], as well 
as support for failure of other organs, including the heart and kidneys. The risk o f thrombotic 
complications is increased, even when compared to other viral respi[INVESTIGATOR_10711], such as 
influenza.5 While 82% of hospi[INVESTIGATOR_41374] -19 are ultimately discharged alive ,6 
median length of stay is 10 -13 days .7 Clinical trials in COVID -19 inpatients are needed to find better 
strategies to prevent or treat progression to critical illness, multiorgan failure, or death.  
Early work in treating COVID -19 has focused on preventi ng worsening of the initial clinical 
presentation  to prevent hospi[INVESTIGATOR_191553] h. Studies 
conducted under this Master Protocol are expected to extend our knowledge of how to manage 
patients who are hospi[INVESTIGATOR_18552] d for COVID -19 illness.   
This protocol intends to define effective therapeutic regimens in a randomized trial  of patients 
hospi[INVESTIGATOR_21391] -19. The primary outcome is oxygen free days through day 28.  
Study number : [ADDRESS_227688] Tissue  
Protocol Version: 5.[ADDRESS_227689](s) to COVID -[ADDRESS_227690] adults with SARS -CoV-2 infection recover after a brief illness with fever, cough, and fatigue or 
similar symptoms. Current therapi[INVESTIGATOR_191554] (ARDS) .8–10 The SARS -CoV-
2 virus enters pulmonary and myocardial cells by [CONTACT_191635][INVESTIGATOR_191555] -Converting Enzyme 2 (ACE2) receptor, a key actuator in the renin -angiotensin -
aldosterone system (RAAS). Thus, in COVID -19, RAAS has been directly implic ated in the 
pathogenesis of ARDS  as part of the host tissue response . ACE2 catalyzes the conversion of 
Angiotensin II (AngII) to Ang(1 -7). When ACE2 is not present AngII remains at increased levels 
stimulating vasoconstriction, the production of inflammato ry cytokines, and pulmonary fibrosis.[ADDRESS_227691] tissue response is important to consider in patients hospi[INVESTIGATOR_121058] -19. ACE/Ang II signaling in human disease is suggested by [CONTACT_191636].15–[ADDRESS_227692] higher 
ACE and Ang II levels in tissue and serum19 and these patients are at higher risk of death from 
ARDS in multiple large cohorts .19–21 Restoration of ACE2 through the administration of recombinant 
ACE2 in a phase II trial of ARDS in humans (n=44) appeared to safely reduce AngII levels and 
increase Ang(1 -7) levels without causing significant hemodynamic changes.22 Further, up to 20% of 
patients with COVID -19 develop myocardial injury, which has been independently associated with 
increased arrhythmias, shock and mortality.23–25 ACE2 receptors are present in cardiac myocytes 
and fibroblasts and the endothelium of coronary arteries, and the ACE2 receptor has been 
implicated as a potentia l mediator of cardiac injury in COVID -19.26 Thrombotic events are a known 
complication in patients hospi[INVESTIGATOR_21391] -19. In vitro evidence suggests, R406, the active 
component of fostamatinib, can inhibit the Fc -mediated release of proinflammatory cytokines by 
[CONTACT_191637] -mediated thrombosis provoked by [CONTACT_7544] -CoV-2 specific spi[INVESTIGATOR_191556]/antibody complexes. Furthermore, R406 also has been shown to in hibit the release of 
neutrophil extracellular traps from neutrophils stimulated with plasma from patients with COVID -19. 
Taken together, it is hypothesized that fostamatinib will decrease the inflammatory milieu generated 
through Fc -activation, ultimately resulting in decreasing immunothrombosis. Preventing 
immunothrombosis in the pulmonary vasculature could mitigate lung injury and hasten recovery 
from COVID -19.   
Recent large -scale cohort studies, however, have not found an association between current use of 
RAAS inhibitors and either increased risk of contracting COVID -19 infection or increased risk of 
severe disease from COVID -19.27,28 Two randomized trial s in patients h ospi[INVESTIGATOR_21391] -19 
who were already taking RAAS inhibitors found no benefit of stoppi[INVESTIGATOR_191557] (BRACE CORONA , REPLACE COVID ).29–[ADDRESS_227693] mechanisms of action. TRV027 and Ang (1-7) both work to restore 
AngII balance by [CONTACT_191638]2 receptor via different mechanisms of improving 
the Ang(1 -7) to AngII ratio. (Figure 1) . Recent data from two Phase II trial s suggest ed that 
fostamatinib  may have substantial imp act on outcomes in patients hospi[INVESTIGATOR_21391] -19, 
Study number : [ADDRESS_227694] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
providing compelling rationale for including this agent on our platform . A recent placebo -controlled 
randomized phase 2 study in hospi[INVESTIGATOR_191558] -19 ([STUDY_ID_REMOVED]) suggested 
fostamatinib in addition to usual care was safe and did not result in more serious adverse events 
(10.5% in the fostamatinib group vs. 22% in the placebo group). Additionally, multiple secondary 
efficacy endpoints showed trends favoring the patients receiving fostamati nib, including 28 -day 
mortality, days free of oxygen, and recovery as measured on the 8 -point ordinal scale at day 15.  
 
Figure 1. Adapted from Alhenc -Gelas and Drueke 2020; The physiological steps of the generation of 
angiotensin II and angiotensin [ADDRESS_227695] from angiotensin II. Angiot ensin 1 -7 activates the Mas receptor.  
3.4 Potential Risks & Benefits  
Participating in this Master Protocol include s risks related to the treatment, as well as risks related 
to privacy and confidentiality. Benefits include the potential for benefit of the ther apeutic strategy, 
increased attention to the participant’s treatments and clinical course when compared with usual 
care, and the global societal benefit of contributing knowledge about COVID -[ADDRESS_227696] 
tissue response for improving clinical outcomes among adults hospi[INVESTIGATOR_21391] -19. 

Study number : [ADDRESS_227697] Tissue  
Protocol Version: 5.[ADDRESS_227698] practice  may itself be updated as therapi[INVESTIGATOR_191559] (or ineffective).  
4.[ADDRESS_227699] tissue response, including 
counterbalancing RAAS activity , on mortality and outcomes related to ARDS. A further objective is 
to determine which of the different RAAS agents ’ targets (AT1r biased agonist, Ang[1 -7] infusion) 
and associate d mechanisms of action, when added to current best practice and compared to 
current best practice  plus placebo , result in an effective therapeutic approach to the RAAS system  
in patients infected with SARS -CoV-2. 
4.2 Study Hypothesis  
We hypothesize the admini stration of Ang  (1-7), TRV027 , or fostamatinib  (all dosed individually, no 
combinations)  will improve  clinical outcomes and will result in improvement in oxygen -free days 
through day 28.  
[ADDRESS_227700] of stratum (i.e., site) 
heterogeneity on assessments of treatment effect . Allocation will be equally distributed across arms 
for which the participant is eligible.  
5.3 Study Outcomes  
5.3.1  Primary Study Outcome  
The primary outcome for this platform is oxygen free days (OFD) at day 28. It is designed to assess 
lung function as determined by [CONTACT_191639] 28 days following 
randomization. This is an important patient -centric outcome refle ctive of recovery  from SARS -CoV-2 
infection. Additional rationale for the primary outcome is explained in detail in Appendix A: P rimary 
study outcomes . OFD is a clinically relevant, longitudinal measure of lung function and mortality 
assessed at [ADDRESS_227701] trial on the 
Adaptive COVID -19 Treatment Trial  platfor m (ACTT -1)[ADDRESS_227702] 28 days 
Study number : [ADDRESS_227703] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
after randomization, defined as time between randomization and the earlier of hospi[INVESTIGATOR_191560] -hospi[INVESTIGATOR_191561] -19. Oxygen free days 
was selected over time to recovery, as defined in ACTT -1, as the primary outcome for our proposal  
for two reasons: (1) to capture home oxygen use as part of the primary outcome; an d (2) to 
incorporate the competing risk of death into the primary outcome using  the same meth odology 
commonly used  for other outcomes evaluating duration of organ support, such as ventilator free days.     
 
OFD will be calculated as the number of calendar days during the first 28 days after randomization 
during which the patient was alive and not receiving new supplemental oxygen therapy.39 Patients 
will be considered to be receiving supplemental oxygen therapy when they are receiving any of the 
following: supplemen tal oxygen by [CONTACT_21294], supplemental oxygen by [CONTACT_143432], high flow 
nasal cannula (HFNC), non -invasive ventilation (NIV), invasive mechanical ventilation (IMV), or 
extracorporeal membrane oxygenation (ECMO). The day of randomization is denoted as Day 0. 
Starting with calendar day 1 (the day after randomization) and continuing for [ADDRESS_227704] leve l of respi[INVESTIGATOR_191562] 8-category WHO COVID -19 clinical status 
scale . Categories 4, 5, 6, and 7 indicate in -hospi[INVESTIGATOR_191563].   
 
Use of supplemental oxygen at home after discharge wi ll be assessed  via telephone follow -up calls  
and text/email responses  to the participant or surrogates . Patients who chronically used 
supplemental oxygen prior to their COVID -19 illness will be considered oxygen free when they 
return to the same level of oxygen support , they had been using prior to COVID -19 illness . For 
example , a patient who chronically used supplemental oxygen at 4 liters per minute via nasal 
cannula before COVID -19 and who was intubated for acute management of COVID -19 would be 
consider ed oxygen free for  calculation of the primary outcome when he/she returned to oxygen 
support via nasal cannula at [ADDRESS_227705] day of follow -up is the day 
after randomization, so 28 OFDs are the maximum possible days  (Appendix A: P rimary study 
outcomes ). 
 
5.3.2  Secondary Outcomes  
• Alive and oxygen  free at days 14 and 28  
• Alive and respi[INVESTIGATOR_33078] -free at days 14 and 28  
• Alive and free o f new invasive mechanical ventilation at 14 and 28 days 
• In-hospi[INVESTIGATOR_307], 28-day, 60-day and 90-day mortality  
• WHO 8 -point ordinal scale at 14 , 28 and 60 days  
▪ 1: Ambulatory – Not hospi[INVESTIGATOR_057], n o limitation of activities  
▪ 2: Ambulatory – Not hospi[INVESTIGATOR_191546] l imitation of activities  or home 
oxygen therapy  
▪ 3: Hospi[INVESTIGATOR_191547] – Hospi[INVESTIGATOR_057], no oxygen therapy  
▪ 4: Hospi[INVESTIGATOR_191547] – Oxygen by [CONTACT_88543]  
▪ 5: Hospi[INVESTIGATOR_191548] – Non-invasive ventilation of high -flow 
oxygen  
▪ 6: Hospi[INVESTIGATOR_191548] –Invasive mechanical ventilation  
▪ 7: Hospi[INVESTIGATOR_191548] – Invasive mechanical ventilation plus 
Study number : [ADDRESS_227706] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
additional organ support with -vasopressors, RRT, or ECMO  
▪ 8: Dead  
• Support -free days to Day 28, including:  
▪ Hospi[INVESTIGATOR_307] -free days  
▪ Respi[INVESTIGATOR_1399] -free days  
▪ Ventilator -free days  
 
Alive and respi[INVESTIGATOR_1399] -free at day [ADDRESS_227707] on nonfatal outcomes will be performed.  A 
respi[INVESTIGATOR_1399] -free day is defined as  a day alive without the use of HFN C, NIV , IMV, or ECMO . 
Participants that are alive but not hospi[INVESTIGATOR_191564].  
5.3.3  Exploratory Outcomes  
Exploratory  outcomes will include the following  (further defined in Appendix C: Minimum Biological 
Specimen collection ): 
• Myocardial injury described by [CONTACT_191640], during and after therapy during 
hospi[INVESTIGATOR_059]  (when possible, at participating U.S. sites) .  
• Myocardial function described by c hanges in NT -proBNP before, during and after therapy 
during hospi[INVESTIGATOR_059]  (when possible, at participating U.S. sites) .   
• RAAS mechanistic biomarkers (AngII, Ang(1 -7), ACE and ACE2) before, during and after 
therapy during hospi[INVESTIGATOR_059]  (measured in samples from a subset of participants, when 
possible  and applicable , at participating U.S. sites) .  
• Renal outcomes: acute kidney injury (following KDIGO) defined as > KDIGO Stage 2 and 
changes in serum creatinine and estimated Filtration Rate  during hospi[INVESTIGATOR_059]  
• Trajectories of biomarkers related to COVID -19 during hospi[INVESTIGATOR_059]  (when possible, at 
participating U.S. sites).   
 
Exploratory outcomes may be collected  at just a subset of sites . 
5.3.4  Safety Outcomes (systematically collected during index hospi[INVESTIGATOR_059])  
Safety outcomes will be measured to reflect the expected adverse consequences of therapeutic 
strategies.  
• Hypotension as defined by [CONTACT_191641] [1] initiation or 
increase in vasopressor therapy, [2] administration of a fluid bolus of 500 ml or more, or [3] 
modification  of the dose  or discontinuation of the study drug .   
• Allergic reaction, including rash and angioedema  
• Incident renal replacement therapy  during hospi[INVESTIGATOR_059]  
 
[ADDRESS_227708] be fulfilled at the time of randomization.  
6.1 Inclusion criteria  
1. Hospi[INVESTIGATOR_18552] d for COVID -19 
Study number : [ADDRESS_227709] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
2. ≥18 years of age  
3. SARS -CoV-2 infection, documented by : 
a) a nucleic acid test (NAT) or equivalent testing within 3 days prior to 
randomization OR  
b) documented by [CONTACT_191642] 3 days prior to 
randomization AND progressive disease suggestive of ongoing SARS -CoV-2 
infection per the responsible investigator (For non -NAT tests, only those 
deemed with equivalent specificity to NAT by [CONTACT_191643]. A central list of allowed non -NAT tests is maintained  in Appendix E. 
Non-NAT Tests Deemed with Equivalent Specificity to NAT by [CONTACT_191644] ).  
4. Hypoxemia, defined as SpO2 <92% on room air, new receipt of supplemental 
oxygen to maintain SpO2  ≥92%, or increased supplemental oxygen to maintain 
SpO2 ≥92% for a patient on chronic oxygen therapy  
5. Symptoms or signs of acute COVID -19, defined as one or more of the following:  
a) cough  
b) reported or documented body temperature of 100.4o F or greater  
c) shortness of breath  
d) chest pain  
e) infiltrates on chest imaging (x -ray, CT scan, lung ultrasound)  
6.2 Exclusion criteria  
1. Onset of COVID -19 symptoms fulfill ing inclusion criterion #5 >14 days prior to 
randomization  
2. Hospi[INVESTIGATOR_191565]  (as defined  in inclus ion #4) for >72 hours prior to 
randomization  (the 72-hour window  for randomization  begins  when  the patient  first 
meets  the hypoxemia  inclusion  criteria  after hospi[INVESTIGATOR_105904])   
3. Pregnancy  
4. Breastfeeding  
5. Prisoners  
6. End-stage renal disease  (ESRD ) on dialysis  
7. Patient undergoing comfort care measures only such that treatment focuses on end -of-
life symptom management over prolongation of life.  
8. The treating clinician expects inability to participate in study procedures or  participation 
would not be in the best interests of the patient  
9. Known allergy/hypersensitivity to IMP or its excipi[INVESTIGATOR_840]  
6.3 Justification of exclusion criteria  
The study medications’ impact on breastfeeding and breastmilk is unknown, and we therefore 
exclude  breastfeeding. We aim to study the impact of early interventions in the hospi[INVESTIGATOR_191566] [ADDRESS_227710] been hospi[INVESTIGATOR_80529] > 72 
hours prior to randomization if the presentation that initiated the current inpatient admission began 
more than 72 hours before randomization, regardless of the initial location of care (e.g., current 
hospi[INVESTIGATOR_191567]) or level of care (e.g., emergency department, hospi[INVESTIGATOR_111494], 
intensive care unit).  
Study number : [ADDRESS_227711] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
6.4 Special screening procedures  
The site investigator or delegate will screen for hospi[INVESTIGATOR_191568] -19 (that is, a positive laborato ry test for SARS -CoV-2) or a pending SARS -CoV-[ADDRESS_227712] the site investigator or delegate for patients with 
a high clinical suspi[INVESTIGATOR_166489] -19 prior to confirmatory testing.  
6.5 Assessment of eligibility  and exclusion tracking  
For patients who appear to meet inclusion criteria during pre-screening, an electronic pre-screening 
form will be completed to determine eligibility and track exclusions. The electronic  pre-screening  
form will be accessed and stored  in the electronic  pre-screening  database. At the time of entry into 
the pre-screening database, the patient will be assigned a pre-screening number.  
If a patient appears to meet all eligibility criteria, the site investigator or delegate will approach the 
treating clinician to ask permission to approach the patient or Legally Authorized Representative 
(LAR) to confirm eligibility, discuss potential stu dy recruitment, and proceed with informed consent.   
For excluded patients  located in the [LOCATION_002] , including refusal by [CONTACT_191645]/surrogate, a small number of de -identified pre-screening variables will be collected including 
month and year the patient met pre-screening criteria, age, sex, ethnicity, and reason(s) the patient 
was excluded. For patients located outside of the [LOCATION_002], no personal information will be 
collected prior to consent, nor stored in the pre -screenin g database. For the safety of research 
personnel and conservation of personal protective equipment (PPE), these encounters may occur 
via telephone or videophone.   
6.6 Process of obtaining informed consent  
Informed consent is a process initiated prior to the i ndividual’s agreeing to participate in the study 
and continues throughout the individual’s study participation. Informed consent should follow both 
local institutional policy and national regulatory guidance including  following institutional COVID 
policy t o protect study staff. Informed consent will be obtained from the patient or from a surrogate 
decision maker if the patient lacks decision -making capacity.    
In some instances, bringing a paper consent form and pen to the bedside of a patient with known o r 
suspected COVID -[ADDRESS_227713] between patients and non -clinical 
personnel. The current pandemic also presents unique challenges to obtaining consent from a 
participant’s LAR. To minimize infectious risk, many institutions are not allowing visitors to enter the 
hospi[INVESTIGATOR_307]. Further more, the LAR is likely to have been exposed to the patient and may therefore be 
under self -quarantine at the time of the informed consent discussion.  
Therefore, in addition to the traditional approach of an in -person consent discussion and signed 
paper in formed consent document , we will allow use of “no -touch” consent procedures for this trial.  
Below, we outline three examples of no -touch consent procedures that may be used: (a) a paper -
based approach; (b) an electronic/e -consent approach; and (c) attesta tion of informed consent.   
6.6.1  Paper -based approach  
1. The informed consent document is delivered to the patient or LAR.  
a. If the patient or LAR is on -site, the informed consent document may be delivered to the 
patient or LAR either by [CONTACT_191646] c linical staff.  
b. If the LAR is off -site, the informed consent document may be emailed, faxed, or otherwise 
electronically transferred to the LAR (method dictated by [CONTACT_10569]).  
Study number : [ADDRESS_227714] Tissue  
Protocol Version: 5.[ADDRESS_227715]/LAR identity.  
3. If the patient or LAR decides to consent to participate, the patient or LAR signs the paper copy of 
the informed consent document.  
4. A photograph is taken of the signature [CONTACT_130179] [CONTACT_191647] (or research staff if onsite  with 
patient/LAR ) of the informed consent document and uploaded into the electronic database ( e.g., REDCap). 
Non-US sites will upload consent images into a local database.  
a. If using the patient’s device (such as a patient’s personal cellular phone), a survey link can 
be sent to their device to allow direct upload of the image into the electronic database  (e.g., 
REDCap).  
b. If using a staff device, it must be approved to store PHI by [CONTACT_7848]. In that case, 
research personnel can take a photograph of the signature [CONTACT_191702] s door leading into the patient’s room.  
The photograph can then be uploaded into the electronic database.  If a staff device is taken 
into the patient’s room to take a photograph it must be able to be disinfected according to 
local institutional practices .  
5. Research staff and the witness provide signatures within the electronic database ( e.g., REDCap) 
confirming their participation in the informed consent process.  
6. The patient or LAR retains the paper consent document. The image of the signature [CONTACT_191703] a copy of the blank informed consent document for research records.  
6.6.2  Electronic/e -consent approach for US sites only  
1. The electronic informed consent document is opened on a research device or a link for the 
electronic info rmed consent document is sent to the patient’s or LAR’s device.  
2. Research staff discuss the informed consent document with the patient or LAR either in person 
or by [CONTACT_191648]. This step confirms subject/LAR identity.  
3. If the patient or LA R decides to consent to participate, the patient or LAR signs the electronic 
informed consent document. This signature [CONTACT_191704]:  
a. an actual signature (often tracing a finger on the screen) OR  
b. a username [CONTACT_191705]  
4. Research staff and the witness, provide signatures within the electronic database (e.g., REDCap) 
confirming their participation in the informed consent process.  
5. The image of the signature [CONTACT_191706] a copy of the blank inform ed 
consent document for research records.  
 
If a hospi[INVESTIGATOR_191569] -based consent, that device will be 
disinfected according to institutional protocols and removed by [CONTACT_191649] t entry into the patient’s room.  
This approach complies with relevant regulations and sub -regulator guidance at 45 CFR 46.117, 45 
CFR 164.512, 21 CFR 11 Subpart C (11.100 –11.300), https://www.hhs.gov/ohrp/regulations -and-
policy/guidance/use -electronic -informed -consent -questions -and-answers/index.html   , 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/informed -consent  . 
The information for the informed consent discussion will be provided in a n informed consent 
document (or electronic equivalent) , that has been approved by [CONTACT_191650] a language 
comprehensible to the potential participant, using an interpreter if necessary. The information 
presented in the co nsent form and by [CONTACT_191651], including any potential risks or benefits of taking part. It will be clearly 
Study number : [ADDRESS_227716] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
stated that the participant is free to withdraw from the trial at an y time for any reason without 
prejudice to future care, and with no obligation to give the reason for withdrawal. Where a patient 
does not speak English, a short -form consent and qualified interpreter will be employed, using 
similar “no -touch” principles.  Use of an interpreter and the interpreter’s identity will be documented 
on the electronic consent.  
6.6.3  Attestation of informed consent  
If none of the options outlined above (traditional signature [CONTACT_191707] a paper consent form, 
electronic photographs of a signed consent page, or e -consent) are available, study personnel may 
attest to completion of the informed consent process using the procedures outlined below.  
Importantly, the process of informed consent using this attestation option should not change 
compared with the traditional method of obtaining informed consent for trial participation except for 
the method of documenting the consent process in the research record. Rather than storing a paper 
document with the participant’s signature, a member of t he research team and an impartial witness 
will attest to completion of the informed consent process and that the participant signed the 
informed consent document. This option of attestation of informed consent is not available when 
obtaining consent throug h a LAR.   
Procedures for attestation of informed consent:  
1. An unsigned paper consent form is provided to the patient by a heath care worker or study member.  
2. The study member obtaining consent arranges an in -person meeting or three -way call or video 
conference with himself/herself, the patient, and an impartial witness. If desired and feasible, 
additional people requested by [CONTACT_102] (e.g., next of kin) may also join this discussion.  
3. A study member reviews consent and answers questions in the presence of the impartial witness.  
4. Patient signs the paper informed consent document while the witness is listening on the phone or 
directly observing.  
5. Patient provides verbal confirmation that he/she would like to participate in the trial , and h e/she 
has signed and dated the informed consent document. This signed informed consent document 
stays with the patient due to the risk of spreading the virus.   
6. Study member and witness attest that other techniques for documenting informed consent were 
not available for this participant and that the participant provided written informed consent for trial 
participation by [CONTACT_2960] a paper informed consent document. An attestation form with signatures 
from the study member and witness will be saved as evide nce of the informed consent process. A 
signature [CONTACT_191708].   
6.[ADDRESS_227717] one active d rug arm, the participant will be randomized m:1 to either the active (will receive 
one of the study drugs) or placebo (will not receive one o f the study drugs) condition. Here, m is the 
number of open study arms for which the patient is eligible. If the patient is eligible for only one agent, 
or only one study arm is open, then allocation is 1:1. For two agents, it is 2:1, for three it is 3:1 a nd so 
on. Once participants are assigned as active or placebo, the participant will then be randomized with 
equal probability to receive one of the active drugs  for which they are eligible , or a corresponding 
placebo (matched by [CONTACT_191652] ). For the purposes of interim and final 
Study number : [ADDRESS_227718] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled 
together as a single group.  In comparing an active drug versus placebo, only those placebo participants 
that were eligible for the active drug will be considered.  Randomization will be implemented using 
permuted blocks , stratified by [CONTACT_191653] . A block size multiplier,  either 1 or 2, will be 
selected uniformly at random for each block. Blocking ensures balance within strata across each active 
and corresponding pooled placebo group and across study arms at the end of each block.  Placebos 
that match the route (e.g., intra venous vs oral) and frequency of the corresponding active agent further 
ensure patient and assessor blinding. Which study arm the participant enters will be known to the 
research sites and the participants, but assignment to active versus placebo will be b linded.  The 
randomized  assignment, concealed from the research team, will be transmitted to the site pharmacy 
who will provide study medication. The participant, treating clinicians, study personnel (other than the 
investigational pharmacist , medical monit or, and the unblinded statistician  who prepare s closed session 
DSMB reports ), and outcome assessors will all remain blinded to group assignment until after the 
database is locked and blinded analysis is completed.  The medical monitor will remain blinded except 
as required for individual patient safety. In cases in which unblinding of the medical monitor is required 
for individual patient safety, assessment of adverse events by [CONTACT_191654].  After assessing adverse events, the medical monitor will communicate directly with 
Coordinating Center to receive the unblinded group assignment needed to inform individual patient 
safety. The medical monitor will not discuss any unbli nded information with blinded trial personnel. If an 
additional adverse event occurs for a patient for whom the medical monitor has been unblinded for 
individual patient safety, an alternate medical monitor will be appointed to review the adverse event and  
determine seriousness, severity, and relatedness.   
 
6.7.1  Emergency Unblinding  
The investigator has the sole responsibility to break the blind in the case of a patient medical 
emergency.  If the investigator believes unblinding the treatment assignment for a par ticipant is 
needed for the safe medical treatment of that participant, unblinding will be discussed and 
information requested from  the Vanderbilt Coordinating Center (VCC). For unblinding requests, 
including emergency unblinding, please contact [CONTACT_191655].  
 
Unblinding will only occur if determined to be required for patient safety or treatment after 
discussion between the site investigator and the Medical Monitor. Stoppi[INVESTIGATOR_191570] t in some cases. If a site investigator 
determines that unblinding may be warranted, the following steps should occur:  
1. Site investigator determines unblinding may be warranted.  
2. Site investigator contacts the VCC by [CONTACT_191656]. The 
unblinding request will be transmitted via the VCC to the Medical Monitor.  
3. Medical Monitor will review the unblinding request and discuss with the site 
investigator regarding the need for unblinding.  
4. If unblinding is determined to be warranted, Medical Monitor documents and 
certifies need for unblinding in REDCap eCRF, accesses the randomized group 
assignment, and transmits this information to the site investigator.  
5.        At sites outside the [LOCATION_002], the site investigator ma y unblind prior to 
contact[CONTACT_31675].  
6.8 Vulnerable Subjects  
Prisoners will not be enrolled due to difficulty obtaining  follow -up for the primary outcome after hospi[INVESTIGATOR_7954]. Children will not be enrolled because children typi[INVESTIGATOR_191571] : [ADDRESS_227719] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
COVID -19 and therefore are less likely to be hospi[INVESTIGATOR_057] (the setting in which this study will be conducted). 
Pregnant women will not be enrolled due to potential teratogenicity of the inv estigational agents.  
This trial may include participants who have no capacity to consent but for whom a LAR may 
provide consent. Patients without the capacity to consent for themselves will have a potential for 
direct benefit by [CONTACT_19212] . Capacity assessment will be conducted by [CONTACT_191657]. When a participant lacks capacity at enrollment, consent will be obtained from the LAR 
before any st udy-related procedures begin. Participants’ capacity will be monitored throughout the 
study by [CONTACT_191658]. If the participant regains the capacity to consent, they will 
be approached for reconsent, including being informed of their par ticipation in the study and having 
an opportunity to withdraw from further participation in the study. Consent from a LAR for persons 
lacking decision -making capacity will conform to local legal requirements.  
6.[ADDRESS_227720], or 
adverse event, does not constitute study withdrawal. Patient data will still be collected as planned 
and analyzed as intention to treat unless the participant withdraw s consent for continued follow -up. 
6.11.2  Premature Termination or Suspension  
The platform, or any arm of the study, may be temporarily suspended or prematurely terminated if 
there is sufficient reasonable cause. Circumstances outside of interim analyses that may warrant 
termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants in a strategy, 
such as excess mortality or serious adverse treatment effects  
• Insufficient compliance to the protocol requirements  
• Insufficient accrual in a study arm  
 
If the platform stops for safety, noncompliance, or data quality, it may resume once such concerns 
about safety, protocol compliance, or data quality are addressed and satisfy the requireme nts of 
appropriate oversight bodies including but not limited to the sIRB, the DSMB, and the FDA.  
Study number : [ADDRESS_227721] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Decisions to stop a study arm or the platform based on the accruing data are not considered 
premature termination or suspension. They will be guided by [CONTACT_191659]. Such decisions will 
generally be weighed by [CONTACT_4318]. Reasons for stoppi[INVESTIGATOR_191572]  
(DSMB review of AEs)  or demonst ration of inferiority.  
 
7 Study Procedures and Schedule  
7.1 Study interventions  
Study agents are described in the agent -specific appendices.  
A summary of the trial’s schedule of events is listed in Section 7.7 and included in  
Event  Baseline &  
Randomization  Day 
0 Day 1 – Day 28  Discharge  Day 
60  Day 90 
Visit Windows  
 Day 7 and 14 + 1 Day  
Day 21 + 2 Days  
Day 2 8 + 5 Days   + 10 
Days 
 + [ADDRESS_227722] results of SOC laboratory 
assessments   X4 X     
Study -specific blood draws  
• CBC with diff and LFTs in 
fostamatinib arm  X4 X   
 
Study -specific biological specimen 
collection  
• EDTA plasma  
• Serum  X4 X   
 
Respi[INVESTIGATOR_191573] , 
oxygen free days and hospi[INVESTIGATOR_191574]   X4 X  X  
 
WHO Ordinal Scale  X X  X  
Mortality  X X X X X 
Sequential Organ Failure 
Assessment score  X    
 
Initiate treatment  X     
Continue study medication 
treatment   X    
Adverse event monitoring  X X7  X  
Study number : [ADDRESS_227723] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Table 1 (Following  section 7.7). 
Timing of study procedures is based on the day and time of randomization, which sets Day [ADDRESS_227724] dose will correspond to the timing 
of other scheduled medication delivery for the hospi[INVESTIGATOR_307]/unit when possible. If the patient is 
discharged , the study medication will be stopped  unless the oral study medication is  planned to be 
continued in the outpatient setting .  
, On each day the participant is hospi[INVESTIGATOR_191575], study personnel will 
review patient records to confirm administration of study drug and document the number and reason 
for any missed doses. Research personnel will also assess patients daily during hospi[INVESTIGATOR_191576] [ADDRESS_227725] -randomization. If the participant is discharged before the full 28 -day period, data will 
be collected according to a set schedule (Day 1, 3, [ADDRESS_227726] -randomization) beginning at 
the next corresponding day post -discharge. This includes data regarding oral study medication 
administration in those subjects who are randomized to arms with oral study medication . These 
assess ments may be completed by [CONTACT_191660] (email, text, or survey link) if the patient 
has been discharged from the hospi[INVESTIGATOR_307].  Patients in the fostamatinib arm could require an in -person 
visit depending on their clinical profile at the time of disch arge. This is further defined in Appendix D: 
Arm 3: Fostamatinib . At day [ADDRESS_227727] will be made at day 90 to assess vital status.   
7.2 Expedited Critical and Major Event Reporting  
All efficacy and safety outcome events will be assessed and documented in the patients’ study 
records  as outlined in sec tion 13. Events meeting the DSMB -specified expedited reporting  criteria 
must be reported immediately to the coordinating center and no later than 24 hours from knowledge 
of occurrence. Standing SOPs applicable to all sub studies will guide the reporting of adverse 
events to ensure they are assessed quickly and are submitted to the DSMB , IRB(s), sponsor and 
other groups as needed (e .g., FDA). All participating sites will also be expected to comply with any 
local requirements for reporting.  
7.3 Data and Safety Monitoring Plan  
[The data and safety monitoring plan  (DSMP)  is described briefly  in Appendix B: Data and Safety 
Monitoring Plan  and in detail in a separate DSMP document .]  
7.4 Biological specimens  
Participants in this Master Protocol are expected to  contribute biological specimens for discovery. 
The biological specimens to be collected, including collection times, processing requirements, and 
storage and shippi[INVESTIGATOR_007], are described in Appendix C: Minimum Biological Specimen collection , and  
any additions to this minimum specimen collection will be described in relevant appendices.  
7.[ADDRESS_227728] discharge disposition    X   
Study number : [ADDRESS_227729] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
7.6 Co-Interventions  and Co -enrollment  
This trial will control the use of study medications (active and control)  during the treatment window. 
Study arm specific medication contraindications are explained in detail in the study arm specific 
Appendices. All other treatment decisions will be made by [CONTACT_191661]. The decision to administer antiviral medications, including remdesivir or convalescent 
plasma, or immunomodulating medications, including corticosteroids, will be made by [CONTACT_191662]. We expect usual care to evolve a s the study 
progresses , and this will be defined by [CONTACT_191663].  
Sponsor and/or protocol leadership may, based upon convincing new evidence, act in the interest 
of participant protection, and in avoidance of co nfounding, to exclude/dis -allow use of any specific 
concomitant therapy found to be reasonably contraindicated for a well -defined portion of the study 
population. Such a determination may be made, communicated, and implemented by a Protocol 
Clarification M emo until it is reasonable to amend the protocol for other reasons.   
Participants will be asked at screening to agree to refrain from participation in other clinical trials 
until at least the assessment at Day 90 except for trials comparing different appr oaches for 
implementing SOC interventions or those  approved by [CONTACT_80600].  
Co-enrollment in other trials will only be allowed in the US where a co -enrolling trial has been approved 
by [CONTACT_80600] . We will consider several principles when consid ering co -enrollment in the M aster 
Protocol . 
1) This will only apply to clinical trials where there is open label enrollment to facilitate interim and 
final analyses of data for this trial, including treatment interactions, and the attribution of causality of 
serious adverse events and unanticipated problems.  
2) Co-enrollment will not be permitted with  trials involving medications with contraindications to co -
administration with any study drug for which the participant is eligible . This review and consideration 
will be similar to consideration of concomitant medications. This assessment will occur prior to 
randomization in the ACTIV [ADDRESS_227730] Tissue platform.  This ensure s there are no specific drug -drug 
interactions  in the event the patient is receivin g active therapy in the assigned arm .  
3) Trials involving medications impact ing the RAAS pathway will not be considered.  
4) Study procedures for the co -enrolling trial will be considered secondary to the procedures for the 
RAAS MP. We will aim to collect the primary and key secondary outcomes for the co -enrolling trial 
but consider the  overall participant burden when  fulfilling trial procedures for the co -enrolling  trial 
such as additional blood draws and participant assessments . 
5) Co-enrollment prior to  randomization will be documented. The impact of c o-enrollment  on the 
effects of active agents versus placebo on the primary o utcome (i.e., heterogeneity of treatment 
effect) will be examined as a supplementary  analysis.   
We aim to co -enroll with the ACTIV -4a trial  only, an open -label randomized trial now studying the 
impact of P2Y12 inhibitors, SGLT2 inhibitors and crizanlizumab on top of usual care. Patients will 
be randomized in ACTIV -4a to one of these medications at a time in an open label fashion. There 
are no drug -drug interactions with agents  in our platform . Patients co -enrolled in ACTIV -[ADDRESS_227731] less than 5 % of patients  will be co-enrolled in ACTIV -4a.   
Study number : [ADDRESS_227732] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
7.7 On study monitoring  
All patients will be hospi[INVESTIGATOR_191577] a part of routine clinical care, including monitoring by [CONTACT_161009], nurses, 
respi[INVESTIGATOR_46175], and ancillary staff. Clinical a nd laboratory data obtained as part of routine 
clinical monitoring will be collected. Those labs required to evaluate secondary and safety 
outcomes that are not collected as part of usual care will be obtained for the purpose of the study 
protocol as outli ned in section 7.7.6 . 
7.7.1  Laboratory evaluations  
Routine clinical monitoring will follow laboratory results when measured as part of usual care which 
may include daily complete blood count (CBC), renal function (creatinine/eGFR), electrolytes, D-
dimer, CRP , and measures of coagulation (PT/PTT/INR). In the fostamatinib trial a daily CBC  and 
liver function test s will also be performed  while in the hospi[INVESTIGATOR_191578] .  
7.7.[ADDRESS_227733] tissue agent s being 
studied (see  Appendix D ). If a medication considered to be contraindicated with the host tissue 
agent is discovered, treating clinicians will be contact[CONTACT_191664][INVESTIGATOR_191579] e or if th e medication in question can be stoppe d or substituted. Those medications in the 
fostamatinib arm with absolute contraindications  (Appendix D) will be held or study drug stopped. 
When there are relative contraindications t reating clinicians will determine whether an alternative 
medication would be appropriate or whether the risk -benefit ratio favors continuing the medication 
with the known potential interaction.  
7.7.3  Criteria for stoppi[INVESTIGATOR_191580]/stoppi[INVESTIGATOR_191581] ( Appendix D ).  
 
To delineate reasons for study drug discontinuation, if study drug is discontinued the study team will 
be prom pted to indicate why it was discontinued. There will be 3 options to choose from:  
 
1. Logistical - i.e.  loss of IV access, CT scan, transport, etc. – no AE reporting/recording required  
2. Clinical events that did not represent an AE – i.e., Fostamatinib stopped  due to starting 
contraindicated medication – no AE reporting/recording  
3. Due to a possible AE or PSESE –study team directed to go to PSESE or AE reporting page 
in electronic data capture form.  
 
7.7.4  Plan for drug shortages  
In the event of a shortage of study drug at a participating trial site, the trial arm will be suspended at 
that site, but the platform trial will continue .   
7.7.5  Baseline variable collection  
Baseline is defined as the patient’s status at randomization.  Physio logical measurements and 
laboratory result s obtained  in the [ADDRESS_227734] the patient’s 
baseline status:   
1. Confirmation of informed consent for trial participation  
2. Confirmation of i nclusion/e xclusion eligibility criteria for trial participation   
Study number : [ADDRESS_227735] Tissue  
Protocol Version: 5.[ADDRESS_227736] for women of childbearing potential  (WOC BP).  
a. WOCBP are defined as any female  who has experienced menarche, has not 
undergone surgical sterilization (hysterectomy, bilateral salpi[INVESTIGATOR_1656],  or bilateral 
oophorectomy), and has not experienced menopause   
b. Postmenopausal women, defined as someone who has gone through menopause , 
do not have to take a pregnancy test.  
4. Admission data: date and time of presentation, origin (home, skilled nursing facility, 
rehabilitation/ long-term-acute care hospi[INVESTIGATOR_307] , nursing home, outside hospi[INVESTIGATOR_307], outside ICU), 
location at enrollment (ED, hospi[INVESTIGATOR_191582], ICU)  
5. Sociodemographics (such as age, sex, race, ethnicity, height, weight, poverty index)  
6. Study -specific blood draws (AngII, Ang(1 -7), ACE and ACE2 , NTproBNP and Troponin ) as 
indicated for each investigational agent in the Ancillary Biomarker Appendix ( Appendix C: 
Minimum Biological Specimen collection ). 
7. Comorbidities such as: AIDS, Leukemia, Malignant Lymphoma, Hemiplegia, 
Cerebrovascular Diseas e, Prior Myocardial Infarction, Congestive Heart Failure, Peripheral 
Vascular Disease, Dementia, COPD, Connective Tissue Disease, Peptic Ulcer Disease, 
History of Hypertension, HIV positive (without AIDS), Alcoholism, Coronary Artery Disease, 
Solid Tumor, Liver Disease, Diabetes Mellitus, Chronic Kidney Disease  
8. Acute signs and symptoms such as: altered mental status, acute hypoxemic respi[INVESTIGATOR_7518], liver function tests, renal function, coagulation studies, chest imaging results  
9. Sequential Organ Failure Assessment (SOFA)  
10. Chronic use of medication s, such as : corticosteroids, ACE inhibitors, angiotensin receptor 
blockers, non -steroids anti -inflammatory drugs, other s  
11. Receipt of antiviral medications between hospi[INVESTIGATOR_191583] d randomization : 
chloroquine, hydroxychloroquine, remdesivir, lopi[INVESTIGATOR_054]/ritonavir, other s  
12. Receipt of immunomodulators between hospi[INVESTIGATOR_191584] : 
corticosteroids, tocilizumab, sarilumab, interferon β, other s  
13. Receipt of anticoagulatio n and anti -platelet agents between hospi[INVESTIGATOR_191584]  
14.  COVID -19 vaccination status  
15. Receipt of COVID -19 convalescent plasma between hospi[INVESTIGATOR_191584]  
16. Receipt of anti-SARS -CoV-2 monoclonal antibodies between hospit alization and randomization  
17. Receipt of invasive mechanical ventilation, non -invasive ventilation, high -flow nasal cannula, 
vasopressors, and oxygen therapy at randomization  
18. Vital signs  
 
7.7.6  Assessments between hospi[INVESTIGATOR_191540]  
1. On days of study medication  administration (before study administration in those arms 
where study drug is not an infusion)  
a. Adverse events of any grade severity present prior to the infusion  or med ication 
administration  
b. Start and stop (or administration time if oral)  times of the infusion of the 
investigational agent/placebo - and restart time if medication stopped for hypotension  
c. Starting dose of study medication  administration   
d. New adverse events of grade 3-4 severity during and  after study medication 
administration   
2. Recording of specifics of study treatment according to assigned arm  
3. Daily laboratory assessments  as part of routine clinical care (CBC, BMP, LFTs, PT/PTT/INR, 
D-dimer and CRP) .  
Study number : [ADDRESS_227737] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
4. Daily vital signs  (including blood pressure) , secondary outcomes and safety assessment s. In 
the fostamatinib arm a daily CBC and liver function tests will also be performed.   
5. Study -specific blood draws ( AngII, Ang(1 -7), NT-ProBNP and Troponin ) as indicated for 
each investigational agent  in the Ancillary Biomarker Appendix ( Appendix C: Minimum 
Biological Specimen collection ). 
6. Targeted c oncomitant medications administered daily in the hospi[INVESTIGATOR_191585], 
Corticosteroids , antiplatelet/anticoagulation , convalescent plasma , monoclonal Ab’s , 
antibacterial a gents, antiviral agents  against SARS -CoV-2, ACEI’s, ARBs, beta blockers . 
7. Date and time of first receipt of supplemental oxygen, high -flow nasal cannula, non -invasive 
ventilation, invasive mechanical ventilation, vasopressors , and extracorporeal membrane 
oxygenation (if applicable)  
8. Date and time of final receipt of supplemental  oxygen, high -flow nasal cannula, non -invasive 
ventilation, invasive mechanical ventilation, vasopressors  and extracorporeal membrane 
oxygenation (if applicable)  
9. Pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic 
stroke at hospi[INVESTIGATOR_53767] [ADDRESS_227738] ICU admission  
11. Date and time of final ICU discharge  
12. Data and time of hospi[INVESTIGATOR_2345]  
 
7.7.7  Assessments following hospi[INVESTIGATOR_191586] 90 days following randomization . The following data will be collected:  
1. Number and reason for missed doses of study drug (only for those discharged prior to 
completing study drug if applicable)  
2. Date of death (if applicable)  through day 90  
3. ED visits, hospi[INVESTIGATOR_5394], and use of supplemental oxygen , HFNC, NIV, IMV or 
ECMO  after hospi[INVESTIGATOR_191587] 60 
4. Safety outcomes  (section 5.3.4 ) after hospi[INVESTIGATOR_191588] 13 at day 28 and day 60 (or if discharged earlier 
as outlined in section 7.1) 
5. New or worsening s ymptoms not previously present at day 28 and day 60 (or if discharged 
earlier as outlined in section 7.1) including fever, chills, cough, chest pain,  dyspnea, 
headache, sore thro at, congestion, runny nose , fatigue , body aches  
 
  
Study number : [ADDRESS_227739] Tissue  
Protocol Version: 5.[ADDRESS_227740]. Only perform if patient is hospi[INVESTIGATOR_057].  
2 Perform for all women of childbearing potential.  
3 Perform only if not completed for current admission.  
4 Perform prior to treatment admin istration  
5 Only in the fostamatinib arm if not performed as part of usual care – performed daily while on study drug as an inpatient. 
A repeat CBC, LFTs and BP check may be necessary depending on values at discharge as indicated in Appendix D: Arm 
3: Fostamatinib . 
6 Coordinate with clinical lab draws when possible - as delineated in Appendix C : Minimum Biological Specimen collection   
[ADDRESS_227741] -randomization if patient is discharged before 28 days.  
8 Administration route and timing/frequency is treatment specific  Event  Baseline &  
Randomization  Day 
0 Day 1 – Day 281 Discharge  Day 
60  Day 90 
Visit Windows  
 Day 7 and 14 + 1 Day  
Day 21 + 2 Days  
Day 2 8 + 5 Days   + 10 
Days 
 + [ADDRESS_227742] results of SOC laboratory 
assessments   X4 X     
Study -specific blood draws5 
• CBC with diff and LFTs in 
fostamatinib arm  X4 X   
 
Study -specific biological specimen 
collection6 
• EDTA plasma  
• Serum  X4 X   
 
Respi[INVESTIGATOR_191573] , 
oxygen free days and hospi[INVESTIGATOR_191574]   X4 X  X7  
 
WHO Ordinal Scale  X X  X  
Mortality  X X X X X 
Sequential Organ Failure 
Assessment score  X    
 
Initiate treatment8 X     
Continue study medication 
treatment   X    
Adverse event monitoring  X X7  X  
Record discharge disposition    X   
Study number : [ADDRESS_227743] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 
8 Statistical Considerations  
This section describe s the statistical approach for each comparison of active treatment  versus  its 
concurrent and eligibility matched placebo comparator  group .   
8.1 Statistical and Analytical Plans  
There will be a formal Statistical Analysis Plan (SAP). This SAP will provide detailed descriptions of 
all primary, secondary, and sensitivity analyses, all interim and final decision thresholds, and all 
required documentation to ensure the reproducibility  of statistical analyses . The SAP will be 
finalized prior to the first interim analysis for the platform, and arm -specific SAP amendments (if 
required)  will occur before the first interim analysis involving that arm.  The finalized SAP will take 
precedence and override the statistical considerations described in this section of the master 
protocol (i.e., Statistical Considerations).  
8.2 Analysis Datasets  
All sub studies conducted under this protocol will use a  modified  intention -to-treat ( mITT) approach 
for primary analyses. The mITT analysis dataset  (i.e., the “full analysis set”)  will include all 
randomized participants according to the treatment assigned at randomization re gardless of 
subsequent compliance or protocol violations , with the  following exceptions: Participants  who do not 
receive study drug will be excluded  from the mITT analysis dataset . Those patients who were 
randomized and found to be ineligible will be excluded from the mITT analysis dataset.  The safety 
analysis dataset will be produced, which will consist of all participants who received at least one 
dose of study medication grouped by [CONTACT_191665].  No statistical hypothesis tests nor other 
statistical inferences will be made using the sa fety analysis dataset unless requested by [CONTACT_4318].  
Per protocol analyses will not be routinely performed  but may be conducted as sensitivity analyses 
to support the mITT analysis. A key monitoring data point is the count of participants who are 
randomized  and included in the ITT dataset but have not received study drug. We expect this to be 
less than 5% among participants who have completed the study. If this becomes greater than 5% 
during the trial, study leadership will meet with study teams to explore a nd mitigate this issue and 
will ensure the number of patients who receive study drug meets the original enrollment goals. We 
will report results for both the mITT (primary) and ITT datasets.  
8.[ADDRESS_227744] on the odds of greater  values of the primary  outcome  
(i.e., improved lung function through 28 days , as measured by [CONTACT_69618] -free days ). Based on the 
behavior of similar outcomes in prior trials,32–36 we anticipate the distribution of the primary outcome 
to be irregular , with peaks around -1 to 0 and between 22 and 28 days. Thus, we will use a flexible 
semi -parametric approach for the primary outcome analysis.  Estimation and inferences about the 
odds ratio  will be made using Bayesian proportional odds (PO)  logistic regression methods.40,[ADDRESS_227745] of participants concurrently randomized to 
receive placebo who also meet the inclusion and exclusion criteria for that agent.  
The general form of the PO model can be written  in terms of the covariates 𝑋 and an outcome 
variable  𝑌, where probabilities of outcome value y or greater Pr(𝑌≥𝑦|𝑋)=expit (α𝑦+𝑋β) where 
α𝑦 is the intercept for outcome  value  y and expit is the logistic (inverse logit) transformation  and X 
contains baseline covariates and treatment . β represent s the log odds ratio (OR) associated with 
Study number : [ADDRESS_227746] Tissue  
Protocol Version: 5.[ADDRESS_227747]  of treatment  versus  placebo  on the odds  Pr(𝑌≥𝑦|𝑋)(1−Pr(𝑌≥𝑦|𝑋)) ⁄ , for any value y. 
8.[ADDRESS_227748] participants or otherwise retrieve 
participant records. If loss -to-follow -up cannot be avoided, and the information needed to compute 
the primary endpoint is partially known (i.e., censored), we will use likelihood -based methods to 
account for this censoring. For example, if a study participant received supplemental oxyg en every 
day during a 10-day period after randomization , but is then lost to follow -up, the primary outcome is 
only partially known  (i.e., OFDs ≤ 18 in this example ). The PO model provides a convenient 
mechanism to account for  this and other  types of  censo ring using a likelihood -based approach.42 
For observations th at are fully observed, the log likelihood contribution is 𝑙(𝛼,𝛽; 𝑦,𝑥)=
logPr(𝑌=𝑦|𝑋=𝑥). For observations that are left censore d at 𝑦 (e.g., ≤ 18 OFDs) observations , 
the log likelihood contribution is 𝑙(𝛼,𝛽; 𝑦,𝑥)=logPr(𝑌≤𝑦|𝑋=𝑥). The latter  is conveniently 
computed by [CONTACT_191666] 1−expit (α𝑦+𝑥β). Censor ed observations on the primary outcome due to 
loss of follow -up, including observations that are censored with respect to both oxygen requirement  
and mortalit y, will be handled  using this mechanism.  
 
All primary analyses will be implemented using the mITT analy sis dataset as described above (see 
Analysis Datasets ). The intercurrent event of death will be coded as a special value in the primary 
outcome (i.e ., composite strategy).  Censoring in the primary outcome will be modeled using the 
likelihood method  described above . No other intercurrent events will affect the primary outcome 
assessment  (i.e., treatment policy strategy).[ADDRESS_227749] -approximate d 
posterior distribution is identical to the asymptotic sampling distribution of the maximum likelihood 
estimate ; in both cases  a normal distribution centered at the estimate with variance -covariance equal 
to the inverse Hess ian of the log likelihood function . All statistical inferences about the odds ratio will 
be made using this method . Statistical uncertainty about supplementary estimands (e.g., treatment 
difference in  the median  of the primary outcome) will be quantified using the delta method.[ADDRESS_227750] on the odds of greater values of the primary outcome. 
Estimation and inference about the primary estimand  (and supplementary  estimands ) will be 
implemented using Bayesian PO logistic regression methods , adjusting for the active drug vs 
placebo  indicator variable , age group (18 -30, 31 -65, >65 years) , sex  at birth , baseline W HO COVID 
Study number : [ADDRESS_227751] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
ordinal outcome score at baseline . Evidence for efficacy will be quantified using  the posterior 
probability that the active agent  versus placebo  odds ratio  is greater than  one (i.e., treatment is 
associated with greater oxygen  free days at day 28). This is denoted the “efficacy  probability ” or 
𝑃(OR>1|Data ), where OR represents the odds ratio , and Data represents the available outcome 
data.  The posterior probability for inferiority/harm is defined as 𝑃(OR≤1|Data ). The primary 
analysis will be implemented separately for each study agent, where the matching placebo group 
will consist of concurrently randomized participants meet ing the inclusion a nd exclusion criteria for 
that agent.  The primary and supplementary  estimands will be presented with 95% credible intervals.  
While we do not anticipate missing covariate data.  
 
8.6.2  Planned Interim and Final Analyses, Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  
At the final analysis  (only)  for each arm, efficacy will be indicated if the posterior probability for 
efficacy exceeds a  common  threshold. For studies under this master protocol, t he efficacy threshold 
will be selected using statistical simulation to ensure a type -I error probab ility of 2.5% for each study 
agent.   
 
Two planned interim analyses will occur separately for each study arm when the number of 
participants with complete 28 -day follow -up (or were deceased, withdrawn, or lost -to-follow -up by 
[CONTACT_4475] 28) reaches 33% and 6 7% of maximum enrollment for that arm. Interim analyses will be 
executed by [CONTACT_191667]. Participant records that inform the primary outcome must 
unde rgo monitoring prior to interim (and final) analysis. At each interim analysis, a study arm may 
be stopped early if there is evidence for inferiority/harm. The trial will be stopped early if the 
posterior probability for inferiority/harm exceeds 0.95 .  
 
8.6.3  Supplementa ry Efficacy Estimands  
The PO model  is attractive for the analysis of ordinal and quantitative response variables, such as 
the primary outcome, because they directly model the cumulative distribution function from which 
the mean, median , other pe rcentiles, and cumulative probabilities of the primary outcome , stratified 
by [CONTACT_1570] , are easily derived.46 In addition to the odds ratio, the effects of treatment versus 
placebo will be quantified using the  difference in mean, difference in median, and differences in  
clinically relevant pro portions  associated with the primary outcome (e.g., mortality  at day 28: 
Pr(𝑌=−1|𝑋), and oxygen requirement every day until day 28: Pr(𝑌=0|𝑋)). These important and 
clinically meaningful supplementary estimands will be used to describe and communicate the 
treatment effect. The posterior distribution for each of the supplementary  estimands is readily 
computed using standard Bayesian methods.  
 
8.6.[ADDRESS_227752] of treatment on the 
odds that Y ≥ 3 (measured as an odds ratio versus placebo) is the same relative effect as for Y ≥ 4. 
However, e ven when  the PO assumption is strongly violated, the estimated OR remains a simple 
function of the Wilcoxon -Mann -Whitney U -statistic, namely the probability that a randomly chosen 
patient on treatment B has a higher response than a randomly chosen patient on treatment A,[ADDRESS_227753] to violations of  the PO assumption  and provide a 
reasonable global assessment of treatment effectiveness. However, derived quantities such as the 
difference in means  may be more sensitive to violations of the PO assumption. Deviations from 
Study number : [ADDRESS_227754] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
proportional odds will be examined by [CONTACT_191668]  (that preserves ordering)  of the primary outcome  (e.g., alive versus dead  at day [ADDRESS_227755] 10 days at day 28 versus alive and oxygen free for fewer than 10 
days or dead at day 28 , etc.) . 
 
Analysis of partially observed or missing outcome data requires assumptions regarding the 
mechanism by [CONTACT_191669]. The likelihood method described above, 
and other similar methods such as multiple imputation  assume that missing values occur at random 
(i.e., missing at random or MAR). However, because censored and missing values cannot be 
observed , assumptions about the missingness mechanism are not verifiable. In order to assess the 
sensitivity of study findings  to violations of this assumption, we will conduct additional sensitivity 
analyses by [CONTACT_191670]. Specifically, we will perform  sensitivity  analyses that vary 
assumptions about the missing outcomes on the two treatment arms separately. The se analyses 
will consider the following two scenarios 1) each partially observed prim ary outcome in the placebo 
group will be assumed to have taken the highest/best possible value, whereas each partially 
observed primary outcome in the intervention group will be assumed to have taken the lowest/worst 
possible value, and 2)  each partially observed primary outcome in the placebo group will be 
assumed to have taken the lowest/worst possible value, whereas each partially observed primary 
outcome in the intervention group will be assumed to have taken the highest/best possible value. 
These anal yses will be implemented using the primary analysis methodology, including an 
assessment of hypothesis testing outcomes.  
 
Co-enrollment in other studies testing COVID -[ADDRESS_227756] co -enrollment to occur in fewer than 5% of patients enrolled in the trial. However, because 
the decision to co -enroll is not affected by [CONTACT_191671] -[ADDRESS_227757] will be examined in strata define d by (but not limited 
to) respi[INVESTIGATOR_191589] , status of co -enrollment in an open label clinical trial 
of antiplatelet agents (ACTIV -4a), age categor y, SARS -CoV-[ADDRESS_227758] estimates 
will be presented with 95% Bayesian confidence interval. No formal hypothesis testing will be 
implemented for these analyses.  Studies under this master protocol will be sized only for assessing 
efficacy using the primary analysis . Thus, there may be inadequate power to examine differential  
treatment . 
 
Study number : [ADDRESS_227759] Tissue  
Protocol Version: 5.[ADDRESS_227760] and cases to enroll. New arms may be introduced according to scientific and public health 
needs.   
Type -I error and power regarding the analysis of the primary outcome  was assessed based on the 
pooled (across all active and placebo arms) distribution of the primary outcome among the first 100 
participants to complete follow -up and monitoring. The efficacy thre shold was identified using 
statistical simulation under the null hypothesis to ensure the study operating characteristics achieve 
design specifications. Pooled and blinded summaries of oxygen -free days at day 28 were used to 
approximate the distribution of  the oxygen free days in the placebo group. Based on these data, the 
anticipated frequency distribution, mean, and median of oxygen -free days (OFDs) for the placebo 
group, and for the treatment group under hypothetical effect sizes computed using the PO mo del 
are displayed in the table below.  
  Inferiority  Superiority  
OFDs / Odds Ratio  Placebo  0.67 0.80 1.40 1.45 1.50 1.55 1.60 1.65 1.70 
Mean  8.8 6.6 7.5 10.8 11.1 11.3 11.5 11.7 11.9 12.0 
Median  0 0 0 6.5 7.5 9.0 10.0 10.5 12.5 14.5 
P(OFDs >= 2 2) 0.19 0.14 0.16 0.25 0.26 0.26 0.27 0.28 0.29 0.29 
Proportion:            
-1 (death)  0.[ADDRESS_227761] 100  participants  and loss -to-follow -up, partially observed oxygen free days 
were simulated to match the observed frequency of partially observed outcomes, which occurred in 
12% of the first [ADDRESS_227762] 100 participants . All simulation analyses, including those 
Study number : [ADDRESS_227763] Tissue  
Protocol Version: 5.[ADDRESS_227764] the efficacy threshold  for the final analysis 
of the primary outcome . The efficacy threshold w as selected to ensure no more than 2.5% type -I 
error . In this simulation, [ZIP_CODE] replicates were used to ensure ~0.31% simulation margin of error in 
estimating the type -I error rate. The efficacy threshold was identified as 0.9760 . The efficacy and 
inferiority/harm thresholds will be applied as follows:  
Analysis  Rule  Result  
Final analysis (only)  Efficacy probability > 0.976  Conclude efficacy  
Each interim and final 
analysis  Inferiority/harm probability > 0.950  Stop and conclude  
inferiority/harm  
 
Using the selected efficacy and inferiority/harm thresholds, the results of [ZIP_CODE] simulations under 
the null hypothesis, and 1000 simulations per inferiority/efficacy scenario are s ummarized in the 
table below. In these simulations, the type -I error probability was 2.47%. The frequency of stoppi[INVESTIGATOR_191590] 8.6%.  A maximum sample size of 600 participants per arm 
(including  matching placebo) provides gre ater than 85% power to detect an odds ratio of 1.65, 
corresponding to a 3.[ADDRESS_227765] been considered 
clinically imp ortant in prior trials.32–[ADDRESS_227766] with 85% power (MDE85) 
is an odds ratio of 1.65.  The frequency of stoppi[INVESTIGATOR_191591]=1.40 was <1%. When the simulated treatment was inferior/harmful relative to 
placebo, at OR =0.67, a conclusion of inferiority/harm occurred in 83.3% of simulated trials (39.1%at 
the first interim, 27.9% at the second interim, and 16.3% at the final analysis), and the average 
sample size was 193.9 participants receiving the active drug.  
 Null Inferiority  Superiority  
OFDs / Odds Ratio  1.00 0.67 0.80 1.40 1.45 1.50 1.55 1.60 1.65 1.70 
Pr(Efficacy)  0.025  0.000  0.001  0.552  0.631  0.705  0.782  0.826 0.856  0.893  
Pr(Inferiority)  0.108  0.833  0.508  0.003  0.002  0.001  0.000  0.000  0.001  0.000  
Pr(Inconclusive)  0.867  0.167  0.491  0.445  0.366  0.294  0.218  0.173  0.143  0.107  
Average(N)  286.[ADDRESS_227767] of uncertainty in the distribution of the OFD outcome  on the type -
1 error probability , simulations under the null hypothesis were twice repeated assuming a “ mild” and 
“severe ” distribution for the OFD outcome . The mild a nd severe distributions were selected such 
that the unadjusted mortality rate  range d ± 3% relative to the initial simulation. The results of 1000 
simulations in each of the mild placebo and severe placebo scenarios are summarized in the table 
below. In the se simulations, the type -I error probability was 2. 5% and 2.3%.  
 
 Severe  Mild 
 OR = 1.00  OR = 1.00  
Mortality rate 
(death)  0.266  0.206  
Pr(Efficacy)  0.023 0.025   
 
Study number : [ADDRESS_227768] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 Severe  Mild 
 OR = 1.00  OR = 1.00  
Pr(Inferiority)  0.0.119  0.117  
Pr(Inconclusive)  0.858  0.858  
Average(N)  284.0  286.4  
 
Prior to the start of enrollment, initial sample size assessments were based on pooled and blinded 
summaries of OFDs from the PassItOn (convalescent plasma) trial of patients hospi[INVESTIGATOR_190290] -19. The inclusion and exclusion criteria for PassItOn are similar to that for ACTIV [ADDRESS_227769] 
Tissue. In these initial assessments, the estimated MDE85 was OR=1.55. Statistical power was 
subsequently reassessed using OFDs summaries in the first [ADDRESS_227770] Tissue, which demonstrated a m ore severe distribution relative to PassItOn participants 
(23.6% vs 17.6% mortality). The estimated MDE85 was OR=1.[ADDRESS_227771] 200 enrolled 
participants are  consistent with the distribution of OFDs observed in PassItOn (18.6% vs 17.6% 
mortality). After discussion of these findings among the blinded study investigators and study 
sponsor, it was determined that statistical power was sufficient , and no sample si ze adjustment was 
warranted.  
8.[ADDRESS_227772] of active agent versus placebo on the odds of binary and ordinal secondary outcomes 
will be quantified using logistic and PO regression methods, respectively , adjusting for patient 
demographic and clinical factors (see Primary Analysis ). Time -to-event outcomes will be analyzed 
using Cox proportional hazards methods. To incorporate death as an appropriately unfavorable 
possible outcome, deaths will be treated as  censor ed at the end of the evaluation period for the 
endpoint (e.g., Day 28).  Where appropriate, the competing risk of death will be addressed using the 
cause -specific hazards method. The proportion of participants who died at fixed time points ( e.g., 
day 28) will be es timated using Kaplan -Meier methods . In order to preserve consistency across the 
primary and secondary analyses, we will uniformly  apply a Bayesian approach using flat priors. For 
each key secondary outcome, efficacy testing (one -sided) will be assessed usi ng the odds ratio or 
hazard ratio, by [CONTACT_191672] a threshold. Each 
threshold will be selected using either a simulation -based method, or an approach similar to most 
conventional statistical testing proc edures, to ensure each test for efficacy has a type -I error 
probability no more than 2.5%.  Odds ratio , hazard ratio , and differences in proportion s (e.g., death 
at 28 days)  estimates will be presented with a 95% credible interval.  
 
A gatekeepi[INVESTIGATOR_007] /fixed -sequence  testing approach will be used to preserve the type -I error rate across 
tests of the primary and secondary outcomes. Specifically, a conclusion of efficacy regarding the 
primary outcome will be require d prior to testing the key secondary outcomes . The fixed -sequence 
method  will be used to test  the following  key secondary outcomes in the order given: alive and 
respi[INVESTIGATOR_1399] -free at day 28, the WHO 8 -point ordinal scale at day 28 , and mortality at da y 28. 
A one -sided type -I error rate of 2.5% will be used for each test.  This approach preserve s the 
familywise type -I error rate for the family of  primary and key secondary outcomes . Heterogeneity of 
treatment effect may be examined for secondary and safety outcomes, as a function of pre -existing 
patient characteristics and baseline variables.  
Study number : [ADDRESS_227773] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
8.8 Analysis of Safety Outcomes  
Monitoring and reporting of safety events will be conducted continuously  as described  in the Data 
and Safety Monitoring Plan . This s ection describes the assessment  of safety endpoints at the 
interim and final analyses . Agent -specific safety and toxicity endpoints (if any) are  detailed in that 
therapy’s appendix.  The frequencies of adverse events, mortality, and other safety endpoints , and 
the treatment effect on  the odds of these events (i.e., the odds ratio)  will be reporte d with 95% 
credible intervals , using Bayesian ordinal and binary logistic regression metho ds in a manner 
similar to that  described for the analysis of secondary outcomes.  
8.9 Adherence and Retention Analyses  
Receipt of planned therapy will be recorded on case report forms and monitored continuously. 
Should minimum adherence not be achieved routine ly, the arm may require modification.  
Adherence, retention,  and accrual will be reported to the DSMB and may be considered as reasons 
for premature termination or suspension of arms, or the entire platform.  
8.10 Baseline Descriptive Statistics  
All variables wi ll be summarized using median and other quantiles, mean, and Gini’s mean 
difference (a robust measure of variability defined as the mean absolute difference between any two 
patients’ values). Variable summaries will be presented by [CONTACT_1570] . Because treatments are 
randomized , differences in baseline characteristics will not be formally tested with respect to 
treatment groups . Emphasis is placed on describing the patient sample . In the case that inclusion 
criteria differ across the various trea tment arms, treatment specific summaries will be m ade by 
[CONTACT_191673] . 
8.[ADDRESS_227774] oratory analysis.  
9 Measures to Minimize Bias  
9.1 Enrollment/Randomization/Blinding  
All participants meeting eligibility for inclusion will be screened for exclusion criteria. Reasons for 
exclusion will be documented. Monitoring for systematic exclusions will b e continuous and failure to 
screen and enroll without bias may result in termination of a site from the trial.  
To prevent bias in allocation of participants to individual sub  studies or to arms within sub  studies, 
participant eligibility should be confirm ed prior to releasing the randomization allocation. 
Randomization will occur at baseline and will generally be equal across all arms for which a patient 
is eligible unless specified in an arm -specific appendix. Randomization will be stratified by [CONTACT_106100]. 
Blinding of patients, providers,  and study team members to study arm allocation will be employed to 
reduce bias in conducting study activities and evaluations. Special precautions may be needed to 
blind outcomes assessors if patients or investigators are unblinded to treatment assignment . 
10 Source Documents and Access to Source Data/Documents  
Source documents are original documents, data, or records that are created during a clinical study, 
relating to the medical treatment and the history of the participant, and from which study data are 
Study number : [ADDRESS_227775] Tissue  
Protocol Version: 5.[ADDRESS_227776] 
allow access to source docum ents as part of clinical study monitoring and oversight.  
11 Quality Assurance and Quality Control  
Quality assurance (QA) is implemented by [CONTACT_191674] a system of best -practice 
standards, reviews, and corrective actions ensuring products and services are of the highest 
achievable quality. The study team and staff members participate in a num ber of quality activities, 
ensuring the sponsor, OHRP, and FDA research standards are met. QA also encompasses 
independent QA oversight processes verifying the quality of the work through independent reviews, 
qualifications, inspections, and audits, assuri ng research staff members, contractors, and service 
providers are following the best research and professional practices.  
Quality control (QC) activities include data entry checks in the electronic data capture (EDC) 
system, centralized monitoring, in -person or remote site monitoring, and other activities. To monitor 
studies, clinical monitoring staff review research records and regulatory documents. Reports 
generated from the EDC system may also guide discussions with site research staff.  
12 Ethics/Protectio n of Human Subjects  
12.[ADDRESS_227777] ethical standards. The 
trial will be carried out in compliance with the protocol, the ethical principles laid down  in the 
Declaration of Helsin ki, in accordance with the ICH Harmonized Guideline for Good  Clinical 
Practice (GCP), the EU directive  2001/20/EC/EU regulation 536/2014 and other relevant 
regulations.  Further , studies will be conducted in full conformity with Regulations for the Protecti on 
of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 
and/or the ICH E6.  
12.2 IRB/Ethics Committee/Competent Authority  
This trial will be initiated only after all required legal documentation has been reviewed and  
approved  by [CONTACT_191675]’s IRB (serving as the single IRB [sIRB]) / 
Independent Ethics Committee  (IEC) and competent authority (CA) according to national and 
international regulations. The  same applies for the implementation of changes introduced by 
[CONTACT_191676] . A determination will be made 
regarding whether previously consented participants need to be re -consented.  
12.[ADDRESS_227778] by [CONTACT_3486], their 
staff, and the sponsor(s). This confidentiality is extended to cover testing of biological samples and 
genetic tests in addition to the clinical information relating to participants.  
Study number : [ADDRESS_227779] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
All investigators and trial site staff will comply with the requirements of the current General Data 
Protection Regulations (GDPR) where applicable with regards to the collection, storage, processing 
and disclosure of personal information and will uphold the applicable local regulations core principles. 
Personal information collected will be kept secure and data access will be limited to the minimum 
number of individuals necessary for quality control, audit, and analysis.  
The study monitor, other authorized re presentatives of the sponsor, representatives of the sIRB, and 
regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_1275], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy  
records for the participants in this study. The clinical study site will permit access to such records. In 
the case that a pharmaceutical company holds an IND for an agent contributing to this study and on 
which this study relies, the pharmaceutical compa ny supplying study product may also inspect study 
records.  
The study participant’s research information will be securely stored at each clinical site and 
transmitted to and securely stored at the Data Coordinating Center. The study data entry and study 
management systems used by [CONTACT_191677]. Wherever feasible, data will be identified by a Participant ID 
number, and not by [CONTACT_191678]. At the end of the stu dy, all records at a clinical site will 
continue to be kept in a secure location for as long a period as dictated by [CONTACT_191679]/IECs , 
Institutional policies,  country -specific/local  regulations,  or sponsor requirements. On completion of 
the study, de -identified data may be made available to others outside the study team.  
12.[ADDRESS_227780] access to research records to refuse to disclose identifying 
information on research participation in any civil, criminal, administrative, legislative, or other 
proceeding, whether at the federal, state, or local level. By [CONTACT_191680], Certificate s 
of Confidentiality help achieve the research objectives and promote participation in studies by 
[CONTACT_4205][INVESTIGATOR_21783].  
13 Adverse events  
Assuring patient safety is an essential component of this protocol. Use of these ag ents for COVID -
19 raises unique safety considerations. This protocol addresses these considerations through:  
1. Exclusion criteria designed to prevent enrollment of patients likely to experience adverse 
events with receipt of these agents  
2. Proactive education of treating clinicians regarding medication interactions relevant to use of 
these agents in the inpatient setting  
3. On-study monitoring of co -interventions and patient characteristics to intervene before 
adverse events occur  
4. Systematic collection of outcomes relevant to the safety of  these agents in this setting  
5. Structured reporting of adverse events  
The safety and monitoring approach in this platform is aligned with the expected impact of the 
investigational agents in the hospi[INVESTIGATOR_60992] -[ADDRESS_227781] possibly related to the investigational agent. 
Importantly, patients with COVID -19 often experience multisystem illness, including ARDS, cardiac 
Study number : [ADDRESS_227782] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
and renal injury. As a result, many anticipated serious adverse events will be collected as study 
outcomes (protocol -specified exempt serious events (PSESEs ) as listed in section 13.2) and will be 
monitored by [CONTACT_191681]. Adverse events and PSES Es will be monitored to ens ure real -time particip ant protection. 
The safety evaluation of the study intervention include s several components  to be reviewed 
regularly by  [CONTACT_15792] -appointed independent DSMB.  
All other AEs are collected for the study intervention (either the blinded investigational agent  or placebo).  
Events will be reported to regulators and IRBs/ IECs  as appropriate/required.  
Adverse events  and unanticipated problems will be regularly reviewed by [CONTACT_4318].   
The following information will be collected on electronic case report forms, and w ill be regularly 
reviewed by [CONTACT_4318], to evaluate and help ensure safety:  
• Deaths through Day 90  
• Hospi[INVESTIGATOR_191592] 60  
• Protocol -specified exempt serious events  (PSESEs)  (see section 13.2) through Day 60  
• Adverse Events that are Serious  OR are Definitely or Possibly Related  (or of Uncertain 
Relationship)  OR are a Grade 3 or 4 Clinical AE (isolated laboratory abnormalities that 
are not associated with signs or symptoms are not collected)   
We outline the safety data collected in Table 2.  
 
Table 2.  Overview of Safety Data Collection  
  Day 0 –5 Day 14  Day 28  Day 60  Day 90 
All grade 3 and 4 clinical AEs 
(new or increased in severity 
to Grade 3/4)  X Xa Xa Xa 
  
Protocol -specified exempt 
serious events (PSESEs)b X X X X 
  
Recordable AEs that are not 
PSESEs  X X X X 
  
Unanticipated Problems  X X X X  
Mortality  X X X X X 
aParticipants will be asked about all new relevant adverse events which have occurred since the 
last data collection, up to that time point. On these visits , qualifying AEs will be collected.  
bThese are explained and defined in section 13.2.  
 
  
Study number : [ADDRESS_227783] Tissue  
Protocol Version: 5.[ADDRESS_227784] medical occurrence associated with use of the 
study drug or study procedures, whether or not the event is related to the study drug or study 
procedures.  If a diagnosis is clinically evident (or subsequently determined), the diagnosis, rather 
than the individual signs and symptoms or lab abnormalities, will be recorded as the AE.  
 
a. Seriousness :  
 
Serious Adverse Event  will be defined as an adverse event that, in the view of the investigator, 
resulted in any of the following outcomes:  
1. Death  
2. A life -threatening event that places the patient at immediate risk of death  
o Does not include events that, had they been more severe, might have caused death  
3. Inpatient hospi[INVESTIGATOR_1081]  
o As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm  
4. Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or a congenital anomaly/birth defect  
o As per http://www.fda.gov/Safety /MedWatch/HowToReport/ucm053087.htm   
 
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_34502], based on appropriate medical judgment, they jeopardize patient safety or 
require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
b. Causality:   
A Related or Possibly Related Adverse Event  will be defined as any adverse event for which 
there is a "reasonable possibility" of a causal relationship between the study drug or study 
procedure and the adverse event. For each recorded adverse event, investigators will grade the 
strength of the relationship of study drug or study procedure to the adverse ev ent, as follows:  
o Definitely Related : The adverse event meets all three of the following criteria:  (a) a temporal 
sequence from receipt of study drug or study procedure  to the adverse event suggests 
relatedness , (b) the event cannot be explained by [CONTACT_191682] n characteristics of the patient’s 
clinical state or other therapi[INVESTIGATOR_014], and (c) evaluation of the patient’s clinical state indicates to 
the investigator the experience is definitely related to study drug or study procedures.  
o Possibly Related : In the investi gator’s opi[INVESTIGATOR_1649], the adverse event is possibly related to study 
procedures but one or more of the above criteria for “Definitely Related” are not met.  
o Probably Not Related : The adverse event occurred while the patient was on the study but, in 
the opi[INVESTIGATOR_871], can reasonably be explained by [CONTACT_191683]’s clinical state or other therapi[INVESTIGATOR_014].  
o Definitely Not Related : The adverse event was definitely produced by [CONTACT_102]’s clinical 
state or by [CONTACT_43593][INVESTIGATOR_13265] n ot by [CONTACT_191684].  
o Uncertain Relationship : The adverse event does not meet any of the criteria previously 
outlined.  
 
c. Expectedness :  
An Unexpected Adverse Event  is defined as an adverse event that is not listed in the investigato r 
brochure or study protocol or is not listed at the specificity or severity that has been observed.   
Study number : [ADDRESS_227785] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
d. Severity : 
The investigator will evaluate all AEs with respect to both seriousness ( defined  in 13.1.a.  above) 
and severity  (intensity or grade).  AEs will be graded for severity according to the DAIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events  (also known at the DAIDS AE Grading 
Table).  For specific events that are not included in the DAIDS AE Gradin g Table, the generic scale 
listed below is to be used:  
Generic AE Grading Scale  
 
Grade 1   
Events causing no or minimal interference with usual social and functional 
activities, and NOT raising a concern, and NOT requiring a medical 
intervention/ therapy.  
Grade 2  Events causing greater than minimal interference with usual social and 
functional activities; some assistance may be needed; no or minimal 
medical intervention/therapy required.  
Grade 3  Events causing inability to perform usual social and functional activities; 
some assistance usually required; medical intervention/therapy required.   
Grade 4  Events causing inability to perform basic self -care functions; medical or 
operative intervention indicated to prevent permane nt impairment, 
persistent disability, or death . 
Grade [ADDRESS_227786] (AESI)  will be defined  as a pre-specified  event of scientific 
or medical concern that has the potential of being related to study drug and is important to 
understand regardless of investigator classifications.  AESIs included below will be recorded in the 
adverse event eCRF and will require a written narrative.  
13.2 Protocol -specified exempt se rious events (PSESEs)  
Outcomes of acute respi[INVESTIGATOR_4416], COVID -19, and critical illness will be systematically 
collected as Protocol -specified exempt serious events (PSESEs) for all patients .   
 
PSESEs are exempt from adverse event reporting unless :  
1. the event is determined to be Serious and Definitely or Possibly Related  to the study drug or 
study procedures;  
2. the event is determined to be Unexpected and Definitely or Possibly Related  to the study 
drug or study procedures; or  
 
This approach is taken  to avoid creating a n overly cumbersome  safety oversight environment  by 
[CONTACT_191685]. Even as 
they are exempted from expedited reporting requirements, PSESEs will be reviewed regu larly 
(unblinded, by [CONTACT_2939]) by [CONTACT_191686]. PSESEs that meet none of the  criteria above will not be recorded or reported as AEs .  
PSESEs  may occur during the initial hospi[INVESTIGATOR_059], lead to  a re-admission, or occur in a later 
hospi[INVESTIGATOR_10090] -up. The following are  study -specific exempt serious events : 
 
• Death (not Definitely or Possibly Related  to the study drug or study procedures)  
• Neurological Events:  
o Seizure  
Study number : [ADDRESS_227787] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
o Stroke  
• Cardiovascular Events:  
o Hypotension  as defined by [CONTACT_191634] [1 ] initiation 
or increase in vasopressor therapy, [2] administration of a fluid bolus of 500 ml or 
more, or [3] modification of the dose or discontinuation of the study drug.  
o Atrial or ventricular arrhythmia  
o Cardiomyopathy  
o Cardiac arrest  
o Myocardial injury  
o Acute coronary syndrome  
o Hypertension as defined by [CONTACT_191687] [1] 
initiation or increase in antihypertensive medicat ions or [2] discontinuation of the 
study drug   
• Respi[INVESTIGATOR_29343]:  
o Hypoxemia requiring supplemental oxygen  
o Acute respi[INVESTIGATOR_1505]  
o Receipt of non-invasive or invasive mechanical ventilation  
o Receipt of extra -corporeal membrane oxygenation  
• Gastro intestinal events:  
o Elevation in aspartate aminotransferase or alanine aminotransferase  
o Acute pancreatitis  
• Renal events:  
o Acute kidney injury  
o Receipt of new renal replacement therapy  
• Endocrine events:  
o Symptomatic hypoglycemia  
• Hematologic or coagulation events:  
o Neutropenia, lymphopenia, anemia, or thrombocytopenia  
o Venous thromboembolism  
• Dermatologic events:  
o Severe dermatologic reaction (e.g., Steven’s Johnson Syndrome)  
 
A PSESE for “initiation of vasopressor therapy” should be recorded for p atients who newly receive 
any vasopressor at a dose of at least 0.1 mcg/kg/min norepi[INVESTIGATOR_191593] (see table).  A 
PSESE for an “increase in vasopressor therapy” should be recorded for patients receiving a 
vasopressor at a dose of at least 0.1 mcg/k g/min norepi[INVESTIGATOR_191594] a 
doubling of vasopressor dose compared to either the dose at the time of randomization or the 
lowest dose in the prior 24 hours.  
 
Study number : [ADDRESS_227788] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 
 
Note: Consistent with this approach, sites will evaluate a potential adver se event to determine 
whether it is a PSESE. If it is not a PSESE, it will be recorded and reported as an adverse event as 
outlined below . If the event is a PSESE, it will be evaluated for relatedness  and expectedness . If the 
event is Serious and Definitely or Possibly Related, Unexpected and Definitely or Possibly Related  
it will be recorded as both a PSESE and  an Adverse Event. If the PSESE does not meet either of 
these three criteria, then the event will be recorded as a PSESE in the PSESE eCRF as a study 
outcome . A study -specific clinical outcome may also qualify as a reportable adverse event. For 
example, a ventricular arrhythmia the investigator considers Serious and Definitely or Possibly 
Related  to the study drug would be both recorded as a study -specific clinical outcome and reported 
as a Serious and Definitely or Possibly Related Adverse Event.  
13.3 Monitoring and recording adverse events  
The principal  investigator [INVESTIGATOR_191595]. For inpatients through day 28, o n a daily basis the investigator or 
designee will determine if any adverse event has occurred .  For each adverse event, the 
investigator will determine whether the adverse event was serious, whether it was definitely or 
possibly related to study drug or study procedures, whether it was unexpected , and of what severity 
it was . 
The following categories of adverse event s will be recorded as AEs in the Adverse Event case  
report form:  
o Adverse Events that Qualify for Expedited Reporting:  
o Serious Unexpected, and Definitely or Possibly Related Adverse Events [also known 
as “Suspected Unexpected Serious Adverse Reactions” (S[LOCATION_003]Rs)] - adverse events 
that are considered by [CONTACT_191688] , unexpected,  and definitely or 
possibly related to the study drug or study procedures  
o Adverse Events that Qualify for Recording and Routine Reporting  through  Day 60  
o Non-S[LOCATION_003]R adverse events that are ‘Serious and Definitely or Possibly Related or 
of Uncertain Relationship’ OR that are “Unexpected and Definitely or Possible 
Related or of Uncertain Relationship”, regardless of whether they are PSESEs  
o Non-S[LOCATION_003]R adverse events that are Serious and are not PSESEs  

Study number : [ADDRESS_227789] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
o Non-S[LOCATION_003]R adverse events that are Definitely Related, Possibly Related, or of 
Uncertain Relationship and are not PSESEs  
o Non-S[LOCATION_003]R adverse events that are Grade 3 or 4 Clinical AEs and are not PSESEs  
o AESIs  will include a narrative and will be reported in a routine manner  
13.4 Reporting adverse events  
This section describes the schedule for recording and reporting different types of safety events on 
eCRFs. In the care of study participants more information may be  collected and recorded in the 
participant’s medical record. The information collected in the medical record serves as source 
documentation of events (e.g., signs, symptoms, diagnoses) considered for reporting on eCRFs as 
part of protocol data collection.  
 
13.4.1  Adverse Events that Qualify for Expedited Reporting  
Adverse Events that qualify for Expedited Reporting include events that: are Serious , Unexpected  
and Definitely or Possibly Related  (also known as Suspected Unexpected Serious Adverse 
Reactions, S[LOCATION_003]Rs .  Adverse Events that qualify for Expedited Reporting  (S[LOCATION_003]Rs)  must be 
reported to the coordinating center by [CONTACT_191689] 24 hours of site investigators 
becoming aware of the adverse event. The investigator at the study site or designee should  inform 
the clinical coordinating center both by [CONTACT_191690] (Figure 2). The Medical Monitor  may discuss with the site PI [INVESTIGATOR_191596]  (S[LOCATION_003]R) . Events  requiring 
Expedited Reporting (S[LOCATION_003]Rs) will be reported by [CONTACT_191691], 
sIRB, FDA and NHLBI within 7 calendar days of receipt of the report from the study site  (as well as 
CA, IE Cs and other bodies per applicable local regulations for ex -U.S. site s). A copy of the Adverse 
Event case report form will be sent to the FDA,  DSMB, sIRB, and NHLBI and appropriate regulatory 
bodies for ex -U.S. sites per applicable local regulations within  14 calendar days of receipt of the 
report from the study site.  Adverse Events requir ing Expedited Reporting  (S[LOCATION_003]Rs)  are followed 
until the outcome of the Adverse Event  is known. If the outcome of an A dverse Events  is still 
unknown at the time of the final follow -up visit, the outcome will be entered in the database as 
“unknown.”  
In parallel, non -U.S. participant SAEs should be reported to the NEAT ID Sponsor using the study 
specific Safety Event Reporting Form (SER F), within 24 hours of a member of the study team 
becoming aware of the event via e -mail to  [EMAIL_3794]  or via the fax number 
provided on the SERF.  
 
For non -U.S. participants , processing of relevant safety events, including expedited SAE report ing 
pertinent to those ex -US territories, including electronic reporting via EudraVigilance of suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs) via ICH E2B compliant safety reports 
(ICSRs/acknowledgements) will be in line with Directive 2001/20/EC D etailed guidance on the 
collection, verification and presentation of adverse event/reaction reports arising from clinical trials 
on medicinal products for human use (CT -3). 
 
Adverse Events, that qualify for recording, but do not qualify for Expedited Repor ting (i.e., adverse 
events that are not S[LOCATION_003]Rs), will be recorded on the Adverse Event eCRF through day 60. The 
DSMB will review all recorded adverse events during the scheduled meetings. The clinical 
coordinating center will distribute the written summary of the DSMB’s review including the review of 
adverse events to the sIRB. If the DSMB determines the overall  rate of adverse events is higher in 
Study number : [ADDRESS_227790] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
the intervention group than the control group, the coordinating center will notify the sIRB and the 
Food and Drug Administration within 14 calendar days of this determination.  
All deaths are reported on the eCRF for dea ths. Deaths considered definitely or possibly  related 
to the study intervention  (blinded investigational agent/placebo) must also be reported as an AE  
and may qualify for Expedited Reporting .  
 
All deaths that are felt to be possibly or definitely related to study drug would be unexpected (for     
reporting purposes) . 
 
Unanticipated problems are findings discovered during the conduct of the trial that suggest 
participation in the trial may have more risk than was anticipated prior to the i nitiation of the trial.  
Unanticipated problems will also be reported within 14 days of the coordinating center learning 
about them to the DSMB and NHLBI.   
13.4.2  Grade 3 and 4 Clinical Adverse Events  
From Day 0 through Day 60, Clinical Adverse Events that are not PSESEs reaching Grade 3 or 4 
severity level will be recorded on an eCRF. For a Clinical Adverse Event that was present at 
baseline, only those newly reach ing Grade 3 or 4 will be recorded . 
 
Clinical Adverse Events that are not PSESEs reaching Grade 3 or 4 severity level that occur between 
days 0 through  60 will be recorded on an eCRF  at the time of phone follow -up. The date the event 
reache s the indicated grade will be collected to permit time -to-event analyses. These Clinical Adverse 
Events should be assessed for seriousness, relatedness, expectedness, severity  (Section 13.3) and 
unanticipated  problem s. These events should be  report ed on the Adverse Event eCRF . 
13.4.[ADDRESS_227791] pregnancy information on any female participants who 
become  pregnant up to 30 days  after receiving study drug  unless indicated differently in the drug -
specific appendix . The participant will be followed to determine the outcome of the pregnancy.  
 
  
Study number : [ADDRESS_227792] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Figure 1.  Adverse Event and Clinical Outcome Assessment, Recording, and Reporting  
 
 
 
 
  

Study number : [ADDRESS_227793] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
13.5 Medical Monitor  
An experienced medical monitor is assigned to the trial . The medical monitor  will work with the site 
PI [INVESTIGATOR_191597], relatedness, expectedness, and severity . The medical monitor w ill 
work with the Coordinating Center to prepar e sponsor safety report and communicat e as needed 
with the DSMB and the Investigational New Drug (IND) holder through the study safety office or  
other mechanism mutually agreed to and documented. An Urgent Safety Measure (USM) is a 
procedure which is not defined by [CONTACT_191692] . It is the responsibility of the 
investigator to apply the appropriate level of USM for the safety and protection of each participant 
in this study in order to prevent harm . USMs may be applied immediately without prior approval 
from the sponsor, competent aut hority ( CA) or IRB/IEC. However, they must be reported to the 
sponsor and to the PI [INVESTIGATOR_97318] (within 24 hours) who will then inform the CA and IRB/IEC 
according to local regulation.  In addition to the expedited safety reporting mentioned above, the ex -
US sponsor (NEAT -ID) will provide Development Safety Update Reports (DSURs) once a year 
throughout the clinical trial, or on request, to the CA and IRB/IEC. The report will be submitted 
within 60 days of the Developmental International Birth Date (DIBD) of the trial each year until the 
trial is declared ended or as per local regulation, if different.  
 
The medical monitor will remain blinded in all discussions with the study team regarding expedited 
reporting and recording to perform an unbiased assessment o f seriousness, relatedness, 
expectedness, and severity. In the event the monitor and clinical team feel that unblinding is 
needed for safety purposes the monitor will communicate this with the Coordinating Center for 
documentation purposes who will confer treating assignment to the medical monitor. When this 
occurs , an alternate medical monitor will be utilized to review the AE with the study team to 
determine seriousness, severity , and relatedness.  
 
The medical monitor or the DSMB may request enrollment be  halted for safety reasons (e.g., 
unacceptably high rate of Serious Adverse Events ). If the treatment arm  is temporarily halted or 
stopped for safety reasons, IRBs/ethics committees will be informed. The IND holder (s) and 
sponsor (s), in collaboration with the protocol chair and the DSMB, will determine if it is safe to 
resume the study. The sponsor will notify the Site Investigators of this decision. The conditions for 
resumption of the study will be defined in this notification. The Site Investigators will  notify their 
local IRBs/ethics committees of the decision to resume the study.  
14 Risk Assessment  
14.1 Potential risks of other study procedures  
See agent -specific appendices for agent -specific safety risks.   
14.2 Minimization of risk  
Federal regulations at 45 CFR 46.111(a)(1) require that risks to participants are minimized by [CONTACT_191693]. This tria l protocol incorporates 
numerous design elements to minimize risk to patients that meet this human subject protection 
requirement.   
Study number : [ADDRESS_227794] Tissue  
Protocol Version: 5.[ADDRESS_227795] benefits from their participation in this study. 
Administration of these agents may improve clinical outcomes among adults hospi[INVESTIGATOR_190290] -19 infection.  
14.4 Risk in relation to anticipated benefit  
Federal regulations at 45 CFR 46.111 (a)(2) require “the risks to subjects are reasonable in relation 
to an ticipated benefits, if any, to subjects, and the importance of the knowledge that may 
reasonably be expected to result.” Based on the preceding assessment of risks and potential 
benefits, the risks to subjects are reasonable in relation to anticipated bene fits All agents have an 
acceptable safety profile  and have been or  are currently being studied in Phase [ADDRESS_227796] (DSMB)  
The role of the DSMB is to monitor patient safety and integrity of the trial. The full details of the 
DSMB will be provided separately by [CONTACT_191694]. We outline the role of the DSMB 
here. The independent DSMB will be comprised of individuals  with appropriate expertise such as 
clinician scientists in critical care, emergency medicine, pulmonology, nephrology, cardiology, trial 
design, biostatistics, and ethics. The DSMB will review reports. Any post -randomization or 
outcomes data presented by [CONTACT_191695], who will conceal such information from 
the investigator team. These unmasked statisticians will compute the efficacy and inferiority  criteria 
at regular intervals as described previously. The DSMB chairperson will be alerted to any decision 
threshold for stoppi[INVESTIGATOR_191598]. Beyond assessing fidelity to pre -specified adaptations, the 
principal role of the DSMB is to assure the safety of participants in this trial. They will regularly 
monitor data from this trial, review and assess the performance of its operations, and make 
recommendations with respect to aspects of trial conduct such as:  
• Adverse events  
• Evidence of efficacy or a dverse events  
• New external information, early attainment of study objectives, safety concerns  
• Possible modifications in the clinical trial protocol  
• Inadequate performance of the trial overall  
 
[ADDRESS_227797] Keepi[INVESTIGATOR_007]  
16.1 Data Collection and Manageme nt Responsibilities  
Data collection is the responsibility of the delegated clinical trial staff at the site under the 
supervision of the site investigator. The investigator is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data.   
Source document worksheets for recording data for each participant enrolled in the study will be 
provided as needed.  Data  recorded in the eCRF derived from source documents should be 
consistent with the data recorded on the source documents.  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and 
clinical laboratory data will be enter ed into secure, compliant data capture systems provided by [CONTACT_191696] : [ADDRESS_227798] Tissue  
Protocol Version: 5.[ADDRESS_227799] approval of a marketing application in an International Conference on Harmonization (ICH) 
region and until there are no pending or contemplated marketing applications in an ICH re gion or 
until at least [ADDRESS_227800] elapsed since the formal discontinuation of clinical development of the 
study intervention. Study documents may be retained for a longer period, however, if required by 
[CONTACT_427]. No records will be destroyed wit hout the written consent of the sponsor, if 
applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 
longer need to be retained.  
16.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol  and GCP requirements. 
The noncompliance may be either on the part of the participant, the investigator, or the study site 
staff. As a result of deviations, corrective actions are to be developed by [CONTACT_48162].  
 
It is t he responsibility of the site PI/study staff to use continuous vigilance to identify and report 
deviations.  
Protocol deviations must be reported to the sIRB per their guidelines. The site PI/study staff is 
responsible for knowing and adhering to requiremen ts for reporting protocol deviations to the study 
coordinating center and sIRB, and these details will be included in the platform MOP.  Where 
applicable in ex -US territories, guidelines for reporting serious breach of protocol and GCP to the 
appropriate re gulatory bodies will be followed.  
16.[ADDRESS_227801]. A complete audit trail of the locked records will be kept in the data instrument’s history log. 
Users will receive a prompt when locking an entire record. They will be asked to review a PDF copy 
of the entire record to confirm it is the correct record and/or file.  Once the PDF has been reviewed 
and confirmed, the r ecord will be locked. All records that are locked using record -level locking will 
have a duplicate copy of the Portable Document Format (PDF) file automatically stored on a secure 
file server outside of REDCap. The record -locking feature complies with all the requirements 
described in 21 CF R Part 11 for FDA trials and  has been validated at VUMC.  
16.4.2  eConsent  
Informed consent should follow both local institutional policy and national regulatory guidance . One 
option in t his trial is to utilize the REDCap eConsent feature. VUMC has developed an electronic 
consent (eConsent) framework within the REDCap platform allowing research participants to rapi[INVESTIGATOR_191599], tablet , or smartphone. Electronic 
consent forms  can leverage standard REDCap survey features including multi -lingual language 
capacity for information rendering and capture. Upon completion, the system documents the 
Study number : [ADDRESS_227802] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
‘consent transaction’ and stores final, “frozen” consent PDFs in REDCap, allowing resea rchers to 
retrieve information on the consent type, status, and version at any time. Consents are also stored 
in a separate secure document system for redundancy and permanent archival. The REDCap 
eConsent framework has been 21 CFR Part 11 validated at VUM C. 
17 End of Trial 
The “end of the trial” o ccurs when patient enrolment, follow -up, data cleaning and analysis have 
been completed . 
[ADDRESS_227803] of care activities for collecting 
information, such as at routine follow -up visits. Such visits will g enerally be charged to insurance 
unless the visit is required only for research. At mixed visits where both research and clinical care 
occur such as for inpatients enrolled in this trial, clinical care will generally be charged to insurance.   
Study number : [ADDRESS_227804] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
19 Appendix A: P rimary study outcomes  
19.1 Approach to ascertainment and verification of outcomes  
Outcomes will be assessed locally and will not be centrally adjudicated unless specified in the arm -
specific appendix. Outcomes should be assessed by a local investigator or other  qualified study 
team member who is blinded to treatment assignment.  
19.2 Primary outcome: Oxygen  free days  
The primary outcome for this platform is oxygen free days through day 28 ( OFD ). OFD  is a clinically 
relevant, longitudinal measure of lung function and mortality for the first [ADDRESS_227805] 28 days after randomization 
during which the patient was alive and not receiving supplemental oxygen by [CONTACT_21294], face 
mask, high flow nasal cannula (HFNC), non -invasive ventilation  (NIV), invasive mechanical 
ventilation (IMV), or extracorporeal membrane oxygenation (ECMO). The day of randomization is 
denoted as Day 0. Starting with calendar day 1 (the day after randomization) and continuing for [ADDRESS_227806] level of respi[INVESTIGATOR_191600] 8-category WHO COVID -19 clinical status scale ( Table 3).48 Calendar days 
on which the patient received supplemental oxygen (category 4), HFNC or NIV (category 5) , or IMV 
or ECMO (categor ies 6 and 7 ) will be classified as a day with oxygen use .   
 
After hospi[INVESTIGATOR_2345], patients will be assessed for home oxygen use via serial telephone follow -
up calls to the patient or surrogate. During these calls, study personnel will assess for new home 
oxygen use with the following questions:  
 (1) Were you discharged from the hospi[INVESTIGATOR_191601]?  
 (2) Did you use oxygen at any time after hospi[INVESTIGATOR_2345]?  
 (3) Are you still using oxygen?  
(4) If you  received oxygen at any time after hospi[INVESTIGATOR_191602], 
what was the last day you used oxygen at home?   
 
Patients who chronically used supplemental oxygen prior to their COVID -19 illness will be 
considered oxygen free when they r eturn to the same level of oxygen support , they had been using 
prior to COVID -19 illness . For example, a patient who chronically used supplemental oxygen at 4 
liters per minute via nasal cannula before COVID -19 and who was intubated for acute management 
of COVID -19 would be considered oxygen free for calculation of the primary outcome when he/she 
returned to oxygen support via nasal cannula at 4 liters per minute or less . 
 
Data collected reflec ting the patient’s status after day [ADDRESS_227807] 28 days following randomization. OFD will be coded as -1 for patients who died before study 
day 28. Hence, the range for OFD is from -1 to 28 days. Examples of OFDs are shown in Table 4. 
Some patients will enter the trial with supplemental oxygen use  (enrolled while in WHO category 4, 
5, 6 or 7), while others will enter the trial with out oxygen therapy  (enrolled while in WHO category 
3).   
Study number : [ADDRESS_227808] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Table 3.  WHO COVID -19 Clinical Status Scale and its use for enrollment eligibility and 
  calculation of oxygen free days (OFD)  
Category  Category Description  Notes for eligibility 
(baseline status)  Notes for OFD calculation (daily 
status on days 1 – 28) 
[ADDRESS_227809] 
supplemental oxygen via 
nasal cannula or mask  Eligible for enrollment  Classified as day with 
supplemental oxygen use   
5 Hospi[INVESTIGATOR_191603] -flow 
nasal cannula or non -
invasive ventilation  Eligible for enrollment  Classified as  day with 
supplemental oxygen use  
6 Hospi[INVESTIGATOR_191604]  
7 Hospi[INVESTIGATOR_191605] 
(including vasopressors, 
RRT or ECMO)  Eligible for enrollment  Classified as day with 
supplemental oxygen use  
8 Death  Patients who die before 
randomization are not 
eligible for enrollment  Death at any time prior to the 
earlier of hospi[INVESTIGATOR_191606] 
28 is coded as -1 OFD 
The baseline (pre -randomization) clinical status will be used to determine eligibility for enrollment. Clinical 
status will be scored every day the patient is in the  hospi[INVESTIGATOR_191607] 28; these daily scores will be used to 
calculate OFD.  
 
 
 
 
 
 
 
 
Study number : [ADDRESS_227810] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 
Table 4.  Descriptions of OFD Data  
 OFD (days)  Description  
More 
Severe  -[ADDRESS_227811] 28 calendar days 
following randomization.     
 
Less 
Severe  28 Patient survived through day 28 and was free from oxygen use on every 
calendar day after the day of randomization (Day 0) for the first 28 days  of 
follow -up. The patient did not receive oxygen by [CONTACT_21294], face mask, 
HFNC, NIV, IMV, or ECMO at any time between day 1 and day 28.  
19.3 Definitions  
 
19.3.1  ICU Level of care  
Defined as planned admission to ICU.   
19.3.2  Myocardial injury  
Myocardial in jury will be defined as an increase in troponin above the 99th percentile with  or without  
ECG changes consistent with ischemia . This diagnosis is made locally.  
19.3.3  Acute Kidney Injury  
Acute kidney injury after enrollment is defined by [CONTACT_191697] n enrollment . We will define AKI as Stage 2 or higher for 
purposes of our AKI outcome : 
     THREE STAGES:  
• Stage 1: Serum Cr 1.5 –1.9 times baseline, OR ≥ 0.3 mg/dl increase in serum Cr  
• Stage 2: Serum Cr 2.0 –2.9 times baseline  
• Stage 3: Serum Cr ≥ 3.0 times b aseline OR Increase in serum creatinine to ≥ 4.0mg/dl, OR 
Initiation of renal replacement therapy  
 
19.3.4  Disseminated Intravascular Coagulation (DIC) (Overt) – DIC score ≥ 5  
1. Platelet count ≥ 100 K (0); 50 –100K (1 point); < 50K (2 points)  
Study number : [ADDRESS_227812] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
2. Elevated D-dimer: no  increase (0 points); moderate increase (1 point); severe increase (3 
points) according to local criteria.  
3. Prolonged PT < 3 seconds (0 points); 3 –6 seconds (1 point); ≥ 6 seconds (2 points)  
4. Fibrinogen level ≥ 100 (0 points); < 100 (1 point) mg/d L 
 
19.3.5  ISTH Defined Major Bleeding  
Bleeding that:  
1. Resulted in death,  
2. Occurred in a critical organ (intracranial, intraspi[INVESTIGATOR_1304], intraocular, retroperitoneal, 
intraarticular, intramuscular with compartment syndrome, or pericardial), or  
3. Associated with either a d ecrease in the hemoglobin level of at least [ADDRESS_227813] 2 units of packed red cells  
  
Study number : [ADDRESS_227814] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
20 Appendix B: Data and Safety Monitoring Plan  
20.1 Overview  
The purpose of a monitoring plan is to facilitate compliance with good clinical pr actice guidelines 
and federal regulations by: [CONTACT_141006] a plan for verifying that the rights and well -being of 
participants are protected; the reported trial data are accurate, complete and verifiable from source 
documents; the confidentiality of partici pant data is maintained; serious adverse events and 
unanticipated problems are adequately addressed; and the trial is conducted in compliance with the 
protocol, prevailing SOPs, federal regulations, and other relevant requirements. The full Data and 
Safety  Monitoring plan is described in detail in a separate document. The scope and content of this 
monitoring plan is based on the objective, purpose, design,  and complexity of this platform, which is 
a multi -arm, blinded, randomized placebo -controlled trial. The safety profile of the selected agents 
being considered for this platform is based on prior clinical trials in patients with acute illness, both 
COVID -[ADDRESS_227815] verification of consent, 
eligibility, and primary outcomes with targeted verification of other data are sufficient to ensure 
study integrity and protection of the rights and welfare of participants. Th e data and safety 
monitoring plan will be approved by [CONTACT_191698] . The details of 
the scope of monitoring, monitoring personnel, site visits (remote and in -person) are delineated in 
the separate DSMP document.  
 
  
Study number : [ADDRESS_227816] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
21 Appendix C: Minimum Biological Specimen collection  
Baseline specimens to be collected  
Sample Processing  
Biorepository  
 
Study -specific biospecimen collection for exploratory outcomes will be collected, when possible, at 
participating U.S. Sites.  
 
Blood collection times  (4 total timepoints) : 
• Baseline —at time of randomization (Study Day 0).  
• Two time points on study drug (St udy Day 1 + 1 day and Study Day 3 ± 1 day)  
• Within 2-36 hours after inpatient study treatment ends  (or any time on Study Day 5 + 36 
hours for final blood collection in the Fostamatinib arm  for those still hospi[INVESTIGATOR_53481] 5 ) 
 
Standard samples to be collected & volumes at each time point:  
• Plasma – 30.4 mL  
• Serum  – 6 mL 
• Total blood collection at each time point = 36.4 mL  
o  
Peptides/enzymes to be measured at each time point : 
• 1st priority:  
o  Ang-(1-7), Ang II, NT -proBNP and hsTn, (plasma, collected in pretreated tubes)  
o ACE, ACEII activity and level, (serum)  
• 2nd priority:  
o Renin, Ang I , Neprilysin, Prolyl oligopeptidase  
 
Supplies : 
• Source – The University of  Vermont : packages sent to sites with EDTA plasma tubes  
(inhibitor cocktail)  including labels and special tubes   
• Sites – Batch s hippi[INVESTIGATOR_007] (overnight on dry ice)  
 
Note 1:  We anticipate that some sites may not be able to collect & process all the samples and time 
points listed above. We plan to work with those sites to identify more limited time points and/or 
discarded samples that could be collected, processed,  and sent to  the biorepository.  
Note 2: If a participant’s blood specimens are unable to be obtained at the timepoints outlined in 
the protocol due to unforeseen circumstances such as a non -functioning IV, or the patients desire to 
not have blood drawn, this will not be considered a protocol violation.  
 
  
Study number : [ADDRESS_227817] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
22 Appendix D: Arm 3: Fostamatinib  
22.1 Description of active therapy  
Fostamatinib is an oral spleen tyrosine kinase inhibitor FDA approved for the treatment of adult 
patients with chronic immune thrombocytopenia (ITP) who have had insufficient response to previous 
treatment. Fostamatinib is a prodrug with an active metaboli te, R406. R406 is protein bound and has a 
half-life of 15 hours, with 80% of excretion occurring in feces and 20% excreted in urine.  
22.[ADDRESS_227818] thromboinflammation. In vitro  evidence suggests, R406, the 
active component of fostamatinib, can inhibit the releas e of cytokines by [CONTACT_191637] -
mediated thrombosis provoked by [CONTACT_7544] -CoV-2 specific spi[INVESTIGATOR_191608]/antibody complexes. R406 
also inhibits the release of neutrophil extracellular traps from neutrophils stimulated with plasma 
from patients with COV ID-19, ultimately resulting in decreasing immunothrombosis. A recent 
placebo -controlled randomized phase 2 study in hospi[INVESTIGATOR_191558] -19 ([STUDY_ID_REMOVED]) 
suggested fostamatinib in addition to usual care was safe and did not result in more serious  
adverse events (10.5% in the fostamatinib group vs. 22% in the placebo group). Additionally, 
multiple secondary efficacy endpoints showed trends favoring the patients receiving fostamatinib, 
including 28 -day mortality, days free of oxygen, and recovery as  measured on the 8 -point ordinal 
scale at day 15.  
  
Study number : [ADDRESS_227819] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 
Figure 2.  Spleen tyrosine kinase inhibition in COVID -19 (Strich, Generated using Biorender)  
 
22.3 Fostamatinib dose, duration, and route of administration  
We will use a study dose of 150mg orally twice daily for 14 days (28 doses) . This  regimen was 
studied in the recently completed phase 2 trial in patients hospi[INVESTIGATOR_21391] -19. The dose 
may be modified to 100mg according to pre -defined criteria in section 22.7 (Dose Modification 
Considerations and Medication Interactions).  Study medicatio n will be continued as an outpatient if 
the patient is discharged prior to completing 28 doses. If necessary, in patients unable to swallow, 
tablets can be crushed until granular with an approximate particle size <2 mm, added to 
approximately 10 mL of wate r, and stirred to mix before administration through an enteral tube.  
 
While many patients on BiPAP can safely receive oral medications, it may be potentially unsafe to 
administer oral medications to patients at certain times while they are receiving BiPAP therapy due 
to risk of hypoxemia if the mask is removed and/or risk of aspi[INVESTIGATOR_191609] -initiated. Determining whether an oral medication should 
be given to a patient receiving BiPAP therapy is a bedside clinical decision.   
The goal is to administer two doses of study medication each calendar day and approximately [ADDRESS_227820] 4 hours apart from one another. If a dose of 
study medication is entirely skipped, a missed dose should be noted in the electronic data capture 

Study number : [ADDRESS_227821] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
system (REDCap). Skipped doses are not “made up” by [CONTACT_191699]; patients 
should  only receive study drug for a maximum of [ADDRESS_227822] common adverse reactions (≥5% and 
more than placebo) being  diarrhea, hypertension, nausea, respi[INVESTIGATOR_4416], dizzines s, ALT/AST 
increase , rash, abdominal pain, fatigue, chest pain and neutropenia. Warnings and precautions 
included in the US product label include hypertension, elevated liver function tests, diarrhea, 
neutropenia, and embryo -fetal toxicity.  
 
• Fostamatinib  must  be discontinued in case the patient becomes pregnant . 
• Concomitant use with strong CYP3A4 inhibitors  with fostamatinib will increase exposure to 
the active metabolite R406  and may result in increased risk of adverse reactions . Therefore, 
patients that cannot have strong CYP3A4 inhibitors held should be excluded from the 
Fostamatinib arm . Strong CYP3A4 inhibitors that should exclude patients from the 
fostamatinib arm include: Atazanavir, Certinib, Clarithromycin, Cobicistat and cobicistat -
containing coformulations, Idelalisib, Indinavir, Itraconazole, Ketocanazole, 
Levoketoconazole, Lonafarnib, Lopi[INVESTIGATOR_054], Mifepristone, Mibefradil, Nefazodone, Nelfinavir, 
Ombitasvir -paritaprevir -ritonavir plus dasabuvir, Posaconazole, Ribociclib, Ritonavir, 
Saquinavir, Telithromycin, Troleandomycin, Tucatinib, Voriconazole. Novel strong CYP3A4 
inhibitors may be released after the writing of this protocol appendix. If you anticipate the 
patient will require a strong CYP3A4 inhibitor that is not included in the list above, please 
reference this regularly updated list:   https://drug -
interactions.medicine.iu.edu/MainTable.aspx  
  
Fostamatinib itself is a weak CYP3A4 inhibitor and will result in a modest (~1.25 fold) 
increase in CYP3A4 substrates. Medications processed (activated or deactivated) by [CONTACT_191700]3A4 enzyme are here referred to as CYP3A4 substrate medications. Concomitant use 
of CYP3A4 substrate medications with Fostamatinib will modestly decrease the processing 
of the CYP3A4 substrate medication. If possible, CYP3A4 substrate medications should be 
held or have another medication substituted for them. Due to its modest effects, concomitant 
use of CYP3A4 substrate medications is not an exclusion criterion for this trial. However, 
investigators should carefully consider inclusion of patients taking CYP3A4 substrate 
medications with narrow therapeutic windows and should monitor closely for toxicities.   
• For a full list of CYP3A4 substrates, please reference this regularly updated list:  https://drug -
interactions.medicine.iu.edu/MainTable.aspx .  
• All participants who are randomized to this arm should  refrain from drinking alcohol while 
taking study drug.  
Study number : [ADDRESS_227823] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
• Once discharged, WOCBP  must agree to use effective contraception to not get pregnant 
between  the first dose of study drug and  [ADDRESS_227824] day of study drug.   
 
Effective contraception is defined as:  
o A tubal ligation: for many teratogenic (and mutagenic) products, tubal ligation is 
considered a form of contraception, not a form of surgical sterilization (e.g., 
hysterectomy, bilateral oophorectomy).  
o An approved ho rmonal contraceptive such as oral contraceptives, emergency 
contraception used as directed, patches , implants, injections, rings, or hormonally 
impregnated intrauterine device (IUD) . 
Less effective contraception is defined as:  
o  A form of l ess effective contraception is defined as Barrier methods (such as a 
condom used with or without a spermicide or a diaphragm or cervical cap used with 
a spermicide).  
22.6 Fostamatinib Arm -Specific Exclusion Criteria  
The following exclusion criteria  differ from the master protocol criteria:  
1. Randomized in another trial evaluating fostamatinib in the prior 30 days  
 
Study arm exclusion criteria  measured within 24 hours prior to randomization : 
1. AST or ALT ≥ 5 × upper limit of normal (ULN) or ALT or AST ≥ 3 × ULN and total bilirubin ≥ 2 × 
ULN 
2. SBP > 160 mmHg or DBP > 100 mmHg at the time of screening and randomization  
3. ANC < 1000/ µL 
4. Patient is anticipated to require a strong CYP3A inhibitor  (Atazanavir, Certinib, Clarithromycin, 
Cobicistat and cobicistat -containing coformulations, Idelalisib, Indinavir, Itraconazole, 
Ketoconazole, Levoketoconazole, Lonafarnib, Lopi[INVESTIGATOR_054], Mifeprostone, Mibefradil, Nefazodone, 
Nelfinavir , Ombitasvir -paritaprevir -ritonavir plus dasabuvi r, Posaconazole, Ribociclib  Ritonavir, 
Saquinavir, Telithromycin, Troleandomycin,  Tucatinib, Voriconazole) from randomization to [ADDRESS_227825]:  https://drug -interactions.medicine.iu.edu/MainTable.aspx .  
 
5. Patient unable to participate or declines participation in  the fostamatinib arm .  
22.7 Dose Modification Considerations and Medication Interactions  
 
Dose Modifications:  The following dose modifications will be utilized  in patients randomized to the 
fostamatinib  arm (active or placebo) . Those patients who have doses held will only complete 14 
days ( up to 28 doses) of study treatment. Dosing will not extend beyond day 14. Blood pressure will 
be monitored daily in the hosp ital while on study drug  up until the time of discharge .  
 
Hypertension:   
Blood pressure >140/90 should be treated with antihypertensives per usual care.   
 
During the inpatient hospi[INVESTIGATOR_059]:  If systolic BP remains > 160 mmHg or diastolic BP > 100 
mmHg or higher despi[INVESTIGATOR_6521], interrupt study drug. When restarting study drug 
Study number : [ADDRESS_227826] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
once BP is below 160 mmHg systolic and 100 mmHg diastolic, drug dose should be reduced to 100 
mg twice daily or matching placebo for the remainder of the study.  
 
• At the time of Hospi[INVESTIGATOR_2345]:  Patients still on study drug  at the time of hospi[INVESTIGATOR_191610] (see Figure 3): 
 
Figure 3.  Schematic overview of blood pressure considerations and procedures  
  performed for patients still on study drug at the time of hospi[INVESTIGATOR_2345]  
 
  
1) Those with SBP < 160 mmHg and DBP < [ADDRESS_227827] no further BP measurements for study purposes  
2) Those with SBP > 160 mmHg or DBP > [ADDRESS_227828] 
study medication stopped and undergo the following repeat te sting:  
 
1) 7 (+/-2) days after post-hospi[INVESTIGATOR_47850] a repeat blood pressure will be obtained.  
a. If the SBP is < 160 mmHg and DBP is < 100 mmHg no further BP monitoring will be 
performed for study purposes  
b. If the SBP is > 160 mmHg or the DBP is > 100 mmHg a follow -up will be performed 
in 7 (+/ -2) days after the prior visit  
i. At the repeat visit if the SBP is < 160 mmHg and DBP is < 100 mmHg no 
further BP monitoring will be performed for study purposes  
ii. At the repeat visit if the SBP is > 160 mmHg or DBP is > 100 mmHg study 
guidance will recommend BP recheck by a healthcare provider   
Hepatotoxicity:  
Inpatient monitoring:  Liver function tests (LFT’s) will be checked daily during hospi[INVESTIGATOR_191611].   
1) Study drug should be stopped if there is an increase in either:  

Study number : [ADDRESS_227829] Tissue  
Protocol Version: 5.[ADDRESS_227830] or ALT  to greater than or equal to 3 -times the upper limit of normal at the local 
lab AND total bilirubin  to greater than or equal to 2 -times the upper limit of normal at 
the local lab.  
Elevated unconjugated (indirect) bilirubin in absence of other LFT abnormalities – continue study 
drug with frequent monitoring since isolated increase in unconjugated (indirect) bilirubin  may be due 
to UGT1A 1 inhibition.  
 
Outpatient monitoring:  Patients discharged while on study drug with AST/ALT or bilirubin elevated 
> 2x the upper reference limits or up trending from most recent value (but less than the inpatient 
stoppi[INVESTIGATOR_3418]) AND  patients discharged n ot on study drug with either AST or ALT at least [ADDRESS_227831] the following study procedures performed:  
 
1) 7 (+/-2) days post -hospi[INVESTIGATOR_2345] a repeat measurement of AST, ALT and total bilirubin 
will be obtained.  
a. Patients NOT on study drug at the time of repeat LFT measurement :  
*If these repeat measurements are less than [ADDRESS_227832] or 
ALT and less than 2 -times the upper limit of normal for total bilirubin, then no further study 
procedures will be performed related to LFT monitoring.  
*If these repeat measurements are greater than [ADDRESS_227833], ALT and total bilirubin  should be obtained 7 (+/-2) days later . If the 
AST or ALT remain above [ADDRESS_227834] of care by a provider or if no provider followed -up by [CONTACT_3476].  
b.  Patients ON study drug at the time of repeat LFT measu rement :  
*If these repeat LFT measurements are below the upper reference limit of normal continue 
study drug to completion and no recheck is needed.  
*If these measurements remain above the upper reference limit of normal for either AST, 
ALT or total biliru bin but do not meet inpatient stoppi[INVESTIGATOR_3418] (defined above), continue 
study drug and a repeat measurement of AST, ALT and total bilirubin  should be obtained 7 
(+/-2) days later . If this repeat testing remains above the upper limit of normal for AST, AL T 
or bilirubin it should be monitored per standard care by a provider or if no provider followed -
up by [CONTACT_3476].   
*If study drug is stopped (per inpatient stoppi[INVESTIGATOR_191612]) repeat measurement of AST, 
ALT and total bilirubin  should be obtained 7 (+/-2) days later . If this repeat testing remains 
above the upper limit of normal for AST, ALT or bilirubin it should be monitored per standard 
care by a provider or if no provider followed -up by [CONTACT_3476].  
  
Once study drug is stopped for abnormal LFT  values, the study drug will not be restarted .  
 
 
Study number : [ADDRESS_227835] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
 
Diarrhea:  If symptoms become severe (grade 3 or above)  while the patient is hospi[INVESTIGATOR_057] , 
temporarily stop study drug until symptoms resolve to mild (grade 1). When restarting, study drug 
dose should be reduced to 100 mg twice daily or matching placebo for the remainder of the study. 
Study drug should be stopped if diarrhea become s severe in the outpatient setting.  
 
Neutropenia:   
If the absolute neutrophil count  (ANC)  decreases  to less than 1.0x10^9/L , the study drug should be  
discontinue d.  
• If the ANC returns to above 1.0x10^9/L, the study drug may be restarted. When restarting 
the study drug , the dose should be reduced to 100 mg twice daily or matching placebo for 
the remainder of the study.  
• In patients  who restart  fostamatinib  at [ADDRESS_227836]  either:  1) 
repeat  CBC  with differential  within  7 days  of discharge  OR 2) not restart  the medication  if 
they are unable  to repeat  CBC  with differential  in this 7-day time frame.  

Study number : [ADDRESS_227837] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
• A CBC with diff erential  will be checked daily wh ile the patient is in the hospi[INVESTIGATOR_191613]. If the patient is discharged with an ANC < 1.0x10^9/L then a re peat CBC with 
differential  will be performed within 7 days of hospi[INVESTIGATOR_191614] 4 
weeks or until the ANC is >1.0x1 0^9/L.  
• If a patient is found to have an ANC <1.0x10^9/L as part of routine care after hospi[INVESTIGATOR_191615] -up period,  then a CBC with differential should be checked 
weekly for 4 weeks or until the ANC is >1.0x10^9/L.  
• Study drug is not restarted when the ANC remains <1.0x10^9/L Those who are discharged 
with a normal ANC require no further measurement after discharge .    
 
Medication Interactions:  
Patients will be monitored after randomization to ensure the following medi cations are not started 
during study treatment: Atazanavir, Certinib , Clarithromycin, Cobicistat and cobicistat -containing 
coformulations, Idelalisib,  Indinavir, Itraconazole, Ketoconazole, Levoketoconazole, Lonafarnib, 
Lopi[INVESTIGATOR_054], Mifeprostone, Mibefradil, Nefazodone, Nelfinavir, Ombitasvir -paritaprevir -ritonavir plus 
dasabuvir, Posaconazole, Ribociclib, Ritonavir, Saquinavir, Telithromycin, Troleandomycin,  
Tucatinib, Voriconazole) from randomization to [ADDRESS_227838]:  https:// drug-
interactions.medicine.iu.edu/MainTable.aspx .  
  
22.8 Fostamatinib Arm Logistics  
The use of fostamatinib for the proposed indication is investigational and the study will be 
conducted un der FDA IND #154000 and will cross reference IND #152131. Fostamatinib can be 
stored at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 0°C to 
40°C (32°F to 104°F).  Rigel has adequate investigational product and placebo to enroll 300 active 
and 300 placebo patients.  
 
For regulatory reporting purposes, including identification and potential expedited reporting of 
‘S[LOCATION_003]R’ events, the following serious and/or non -seriou s Adverse Events/Reactions are among the 
events that are considered expected for this study:  
• Neutropenia  
• Diarrhea  
• Elevated AST, ALT , or bilirubin . However, AST or ALT greater than [ADDRESS_227839] or the baseline value at the time of  randomization, whichever is greater, is 
considered unexpected for fostamatinib study drug for the purposes of adverse event 
reporting.  
• Hypertension  
 
 
The following is considered an AESI for the fostamatinib arm:  
- AST or ALT greater than [ADDRESS_227840] or the baseline value at the time of 
randomization, whichever is greater  
 
 
 
 
Study number : [ADDRESS_227841] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
23 Appendix E. Non-NAT Tests Deemed with Equivalent Specificity to NAT by [CONTACT_191701]* Updated 
(first issued)  Manufacturer  Diagnostic  
(Letter of 
Authorization)  PPA- Sensitivity  NPA - Specificity  Antigen  Days since 
symptom 
onset  
13-Jan-2021  
(02-Jul-2020)  Becton, Dickinson 
and Company (BD)  BD Veritor System for 
Rapid Detection of 
SARS -CoV-2 84% 100%  nucleocapsid  5 
(11-Jan-2021)  
11-Jan-2021  Ortho Clinical 
Diagnostics Inc.  VITROS 
Immunodiagnostic  
Products SARS -CoV-2 
Antigen Reagent Pack  90.0%  
(76.3 –97.2%)  100%  
(95% CI: 99.1 –
100.0%)   
nucleocapsid  7 
01-May-2021  
(01-May-2021)  Quanterix 
Corporation  Simoa SARS -CoV-[ADDRESS_227842]  97.7 %  
(95% CI: 92.03 -99.72)  100%  
(95% CI: 90.75 -
100.0)  nucleocapsid  14 
23-Dec-2020  
(15-Dec-2020)  Ellume Limited  Ellume COVID -[ADDRESS_227843]  95% 
[95% CI 82% - 99%]  97% 
[95% CI 93% - 99%]  nucleocapsid  w/ or wo/ 
symptoms  
22-Dec-2020  
(18-Dec-2020)  Quidel Corporation  QuickVue SARS 
Antigen Test  96.6%  99.3%  nucleocapsid  5 
16-Dec-2020  
(26-Aug-2020)  Abbott Diagnostics 
Scarborough, Inc.  BinaxNOW COVID -[ADDRESS_227844]  84.6%  
(95% CI: 76.8% - 
90.6%)  98.5%  
(95% CI: 96.6% - 
99.5%)   
nucleocapsid  7 
16-Dec-2020  
(16-Dec-2020)  Abbott Diagnostics 
Scarborough, Inc.  BinaxNOW COVID -[ADDRESS_227845]  91.7%  
(95% CI: 73.0% - 
98.9%)  100.0%  
(95% CI: 87.7% - 
100.0%)   
nucleocapsid  [ADDRESS_227846]  96.9%  
(95% CI: 83.8% - 
99.9%)  100%  
(95% CI:    97.3% - 
100%)  nucleocapsid  [ADDRESS_227847]-2020  
(23-Oct-2020)  Celltrion [LOCATION_003], Inc.  Sampi[INVESTIGATOR_191616] -19 
Antigen MIA   
 
99.4 %   
 
100%  receptor binding 
domains  
(RBDs) spi[INVESTIGATOR_191617]  [ADDRESS_227848]-2020  
(08-Oct-2020)  Access Bio, Inc.  CareStart COVID -[ADDRESS_227849]  88.4 %  100%  nucleocapsid  [ADDRESS_227850]-2020  
(02-Oct-2020)  Quidel Corporation  Sofia 2 Flu + SARS 
Antigen FIA  95.2 %  100%  nucleocapsid  5 
18-Aug-2020  
(18-Aug-2020)  LumiraDx [LOCATION_006] Ltd.  LumiraDx SARS -CoV-
[ADDRESS_227851]  97.6 %  
(91.6 % - 99.3 %)  96.6 %  
(92.7 % - 98.4 %)  nucleocapsid  12 
17Jul  2020  
(08-May-2020)  Quidel Corporation  Sofia SARS Antigen 
FIA 96.7 %  
(96.7% - 99.4 %)  100 %  
(97.9 % - 100.0 %)  nucleocapsid  - 
 
 
Study number : [ADDRESS_227852] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
24 References  
1.  Kashyap S, Gombar S, Yadlowsky S, Callahan A, Fries J, Pi[INVESTIGATOR_191618], Shah NH. Measure what 
matters: Counts of hospi[INVESTIGATOR_191619] a better metric for health system capacity planning 
for a reopening. Journal of the American Medical Informatics Association. 2020 Jul 
1;27(7):1026 –1131.  
2.  Price -Haywood EG, Burton J, Fort D, Seoane L. Hospi[INVESTIGATOR_191620] -19. N Engl J Med. [LOCATION_005] Medical Society; 
2020 May 27;382(26):2534 –2543.  
3.  Xu P, Sun GD, Li ZZ. Clinical characteristics of two human -to-human transmitted 
coronaviruses: Corona Virus Disease [ADDRESS_227853] Respi[INVESTIGATOR_98189]. Eur Rev Med P harmacol Sci. 2020;24(10):5797 –5809. PMID: 32495918  
4.  Nguyen NT, Chinn J, Nahmias J, Yuen S, Kirby [CONTACT_140173], Hohmann S, Amin A. Outcomes and 
Mortality Among Adults Hospi[INVESTIGATOR_45086] -19 at US Medical Centers. JAMA Netw 
Open. 2021 Mar 5;4(3):e210417.  
5.  Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hoc hman J, Berger JS. Thrombosis in 
Hospi[INVESTIGATOR_191621] -19 in a [LOCATION_001] City Health System. JAMA. 2020 Aug 
25;324(8):799.  
6.  Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, Jentz C, Northrup GR, 
Mahmud A, Reingold AL, Peterse n M, Jewell NP, Young S, Bellows J. Incidence, clinical 
outcomes, and transmission dynamics of severe coronavirus disease 2019 in [LOCATION_004] and 
Washington: prospective cohort study. BMJ [Internet]. British Medical Journal Publishing 
Group; 2020 May 22 [ci ted 2020 Sep 17];369. Available from: 
https://www.bmj.com/content/369/bmj.m1923 PMID: 32444358  
7.  CDC. Coronavirus Disease 2019 (COVID -19) [Internet]. Centers for Disease Control and 
Prevention. 2020 [cited 2020 Sep 17]. Available from: https://www.cdc.go v/coronavirus/2019 -
ncov/hcp/clinical -guidance -management -patients.html  
8.  Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spi[INVESTIGATOR_95265], Galli M, Ahn 
MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, 
Gaggar A, Bra inard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, 
Subramanian A. Remdesivir for 5 or 10 Days in Patients with Severe Covid -19. New England 
Journal of Medicine. [LOCATION_005] Medical Society; 2020 May 27;0(0):null.  
9.  RECOVERY Collab orative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell 
L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, 
Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, 
Juszczak  E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospi[INVESTIGATOR_191622] -19 - Preliminary Report. N Engl J Med. 2020 Jul 17; PMCID: PMC7383595  
10.  Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, Huang J, He N, Yu H, Lin X, Wei S, Wu T. 
Associat ion of Public Health Interventions With the Epi[INVESTIGATOR_191623] -19 Outbreak in 
Wuhan, China. JAMA. 2020 May 19;323(19):1915 –1923. PMCID: PMC7149375  
11.  Uhal BD, Li X, Pi[INVESTIGATOR_191624], Molina -Molina M. Angiotensin signalling in pulmonary fibrosis. Int 
J Biochem Cell Biol. 2012 Mar;44(3):465 –468. PMCID: PMC3288339  
12.  Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, Wang K, Han L, Duan Y, Zhao Z, Yang X, Xing L, 
Zhang P, Wang Z, Li R, Yu JJ, Wang X, Yang P. Angiotensin -converting enzyme 2 inhibits 
lung injury in duced by [CONTACT_15206][INVESTIGATOR_4345]. Sci Rep. 2016 Jan 27;6:[ZIP_CODE]. PMCID: 
PMC4728398  
13.  Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, Guo F, Bai T, Han Z, 
Zhu J, Zhou H, Huang F, Li C, Lu H, Li N, Li D, Jin N, Penninger JM, Jiang C. Angiotensin -
converting enzyme 2 protects from lethal avian influenza A H5N1 infections . Nat Commun. 
2014 May 6;5:3594. PMCID: PMC7091848  
Study number : [ADDRESS_227854] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
14.  Liu M, Wang T, Zhou Y, Zhao Y, Zhang Y, Li J. Potential Role of ACE2 in Coronavirus 
Disease 2019 (COVID -19) Prevention and Management. J Transl Int Med. 2020 Mar;8(1):9 –
19. PMCID: PMC7227161  
15.  Wenz  M, Hoffmann B, Bohlender J, Kaczmarczyk G. Angiotensin II formation and endothelin 
clearance in ARDS patients in supi[INVESTIGATOR_191625]. Intensive Care Med. 2000 
Mar;26(3):292 –298. PMID: 10823385  
16.  Doerschug KC, Delsing AS, Schmidt GA, Ashare A. Re nin-angiotensin system activation 
correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit 
Care. 2010;14(1):R24. PMCID: PMC2875539  
17.  Wenz M, Steinau R, Gerlach H, Lange M, Kaczmarczyk G. Inhaled Nitric Oxide Does Not 
Change Transpulmonary Angiotensin II Formation in Patients With Acute Respi[INVESTIGATOR_129639]. Chest. 1997 Aug;112(2):478 –483.  
18.  Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z. Losartan prevents sepsis -induced 
acute lung injury and decreases activation of nuclear factor kappaB and mitogen -activated 
protein kinases. Shock. 2009 May;31(5):500 –506. PMID: 18827741  
19.  Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, Humphries 
SE, Hill MR, Laurent GJ. Angiotens in converting enzyme insertion/deletion polymorphism is 
associated with susceptibility and outcome in acute respi[INVESTIGATOR_1505]. Am J 
Respir Crit Care Med. 2002 Sep 1;166(5):646 –650. PMID: 12204859  
20.  Adamzik M, Frey U, Sixt S, Knemeyer L, Beid erlinden M, Peters J, Siffert W. ACE I/D but not 
AGT ( -6)A/G polymorphism is a risk factor for mortality in ARDS. European Respi[INVESTIGATOR_191626]. 2007 Mar 1;29(3):482 –488.  
21.  Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC. Polymorphism of the angiot ensin -
converting enzyme gene affects the outcome of acute respi[INVESTIGATOR_1505]. Crit Care 
Med. 2006 Apr;34(4):1001 –1006. PMID: 16484896  
22.  Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, 
Tidswell M, Har des K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe 
AI, Lazaar AL. A pi[INVESTIGATOR_191627] -converting enzyme 2 in 
acute respi[INVESTIGATOR_1505]. Crit Care. 2017 07;21(1):234. PMCID: PMC5588692  
23.  Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang 
B, Huang C. Association of Cardiac Injury With Mortality in Hospi[INVESTIGATOR_191621] -
19 in Wuhan, China. JAMA Cardiology. 2020 Jul 1;5(7):802.  
24.  Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular 
Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID -19). JAMA 
Cardiology. 2020 Jul 1;5(7):811.  
25.  Kochi AN, Tagliari AP, Forleo GB, Fassini GM, T ondo C. Cardiac and arrhythmic 
complications in patients with COVID -19. J Cardiovasc Electrophysiol. 2020;31(5):1003 –1008. 
PMCID: PMC7262150  
26.  Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pi[INVESTIGATOR_191628]2 deficiency 
and SARS -CoV-2 infection. European Journal of Internal Medicine. 2020 Jun;76:14 –20.  
27.  Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin –Angiotensin –Aldosterone 
System Blockers and the Risk of Covid -19. N Engl J Med. 2020 Jun 18;382(25):2431 –2440.  
28.  Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, 
Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe 
G, Hochman JS. Renin –Angiotensin –Aldosterone System Inhibitors and Risk of Covid -19. N 
Engl J Med. 2020 Jun 18;382(25):2441 –2448.  
29.  Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll -Bernardes RJ, Feldman A, D’Andréa 
Saba Arruda G, de Souza AS, de Albuquerque DC, Mazza L, Santos MF, Salvador NZ, 
Gibson CM, Granger CB, Alexander JH, de Souza OF, BRACE CORONA investigators. 
Study number : [ADDRESS_227855] Tissue  
Protocol Version: 5.0 dated 202 3.08.07    
 
Continuing versus suspending angiotensin -converting enzyme inhibitors and angiotensin 
receptor blockers: Impact on adverse outcomes in hospi[INVESTIGATOR_191629] 2 (SARS -CoV-2)--The BRACE CORONA Trial. Am Heart J. 
2020;226:49 –59. PMCID: PMC7219415  
30.  Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll -Bernardes RJ, Dos Santos TM, Mazza 
L, Feldman A, D’Andréa Saba Arruda G, de Albuquerque DC, Camiletti AS, de Sousa AS, de 
Paula TC, Giu sti KGD, Domiciano RAM, Noya -Rabelo MM, Hamilton AM, Loures VA, Dionísio 
RM, Furquim TAB, De Luca FA, Dos Santos Sousa ÍB, Bandeira BS, Zukowski CN, de Oliveira 
RGG, Ribeiro NB, de Moraes JL, Petriz JLF, Pi[INVESTIGATOR_191630], Miranda JS, de Jesus Abufaiad BE, 
Gibso n CM, Granger CB, Alexander JH, de Souza OF, BRACE CORONA Investigators. Effect 
of Discontinuing vs Continuing Angiotensin -Converting Enzyme Inhibitors and Angiotensin II 
Receptor Blockers on Days Alive and Out of the Hospi[INVESTIGATOR_191631]-19: 
A Randomized Clinical Trial. JAMA. 2021 Jan 19;325(3):254 –264. PMCID: PMC7816106  
31.  Continuation versus discontinuation of renin –angiotensin system inhibitors in patients admitted 
to hospi[INVESTIGATOR_103182] -19: a prospective, randomised, open -label tr ial - The Lancet 
Respi[INVESTIGATOR_33593] [Internet]. [cited 2021 Jul 12]. Available from: 
https://www.thelancet.com/journals/lanres/article/PI[CONTACT_136186]2213 -2600(20)[ZIP_CODE] -0/fulltext  
32.  Schoenfeld DA, Bernard GR, ARDS Network. Statistical evaluation of ventilator -free days as 
an efficacy measure in clinical trials of treatments for acute respi[INVESTIGATOR_1505]. Crit 
Care Med. 2002 Aug;30(8):1772 –1777. PMID: 12163791  
33.  National Heart, Lung, and Blood Institute Acute Respi[INVESTIGATOR_39053] (ARDS) 
Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, 
deBoisblanc B, Connors AF, Hite RD, Harabin AL. Comparison of two fluid -management 
strategies in acute lung injury. N Engl J Med. 2006 Jun 15;354(24):2564 –2575. PMID: 
[ADDRESS_227856] of Selepressin vs Placebo on Venti lator- and Vasopressor -
Free Days in Patients With Septic Shock: The SEPSIS -ACT Randomized Clinical Trial. JAMA. 
[ADDRESS_227857] 2; PMCID: PMC6802260  
35.  Self WH, Semler MW, Wanderer JP, Wang L, By[CONTACT_34057], Collins SP, Slovis CM, Lindsell CJ, 
Ehrenfeld JM, Siew ED,  Shaw AD, Bernard GR, Rice TW, SALT -ED Investigators. Balanced 
Crystalloids versus Saline in Noncritically Ill Adults. N Engl J Med. 2018 01;378(9):819 –828. 
PMCID: PMC5846618  
36.  Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Col lins SP, 
Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE, Hayden 
DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, 
Robinson BRH, Schoenfeld DA, Shapi[INVESTIGATOR_95178], Steingrub JS, Ulysse CA, Weissman A , Yealy 
DM, Thompson BT, Brown SM, National Heart, Lung, and Blood Institute PETAL Clinical Trials 
Network, Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton -Thompson S, 
De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, See thala R, Johnsky L, 
Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapi[INVESTIGATOR_2152] N, Talmor D, O’Mara T, 
Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner -Goodspeed V, Boyle K, Dubosh N, Filbin 
M, Hibbert K, Parry B, Lavin -Parsons K, Pulido N, Lilley B,  Lodenstein C, Margolin J, Brait K, 
Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, 
Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, 
Study number : [ADDRESS_227858] Tissue  
Protocol Version: 5.[ADDRESS_227859] of Hydroxychloroquine on Clinical Status at 14 Days in Hospi[INVESTIGATOR_125748] -19: A Randomized Clinical Trial. JAMA. 2020 Dec 1;324(21):2165 –2176. PMCID: 
PMC7653542  
37.  Self WH, Stewart TG, Wheeler AP, Atrouni WE, Bistran -Hall AJ, Casey JD, Cataldo VD, 
Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, 
Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, 
Johnson NJ, Jones AE, Laguio -Vila M, Lindsell CJ, Ma llada J, Mammen MJ, Metcalf RA, 
Middleton EA, Mucha S, O’Neal HR, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, 
Schrager H, Shanholtz C, Shapi[INVESTIGATOR_95178], Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, 
Rice TW. Passive Immunity Trial for Our Nation (Pass ITON): study protocol for a randomized 
placebo -control clinical trial evaluating COVID -19 convalescent plasma in hospi[INVESTIGATOR_119800]. 
Res Sq. 2021 Mar 2; PMCID: PMC7941637  
38.  Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu  HY, 
Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, 
Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, 
Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, 
Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, 
Osinusi A, Nayak S, Lane HC, ACTT -1 Study Group Members. Remdesivir for the Treatment 
of Covid -19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813 –1826. PMCID: 
PMC7262788  
39.  Moskowitz A, Shotwell MS, Gibbs KW, Harkins M, Rosenberg Y, Troendle J, [COMPANY_006] LH, Files 
DC, Wit M de, Hudock K, Thompson BT, Gong MN, Ginde AA, Douin DJ, Brown SM, Rubin E, 
Joly MM, Wang L, Lindsell CJ, Bernard GR, Semler MW, Collins SP, Se lf WH. Oxygen -Free 
Days as an Outcome Measure in Clinical Trials of Therapi[INVESTIGATOR_135297] -19 and Other Causes 
Study number : [ADDRESS_227860] Tissue  
Protocol Version: 5.[ADDRESS_227861] [Internet]. Elsevier; 2022 Apr 30 [cited 2022 Jun 7];0(0). 
Available from: https://journal.chestnet.org/article/S0012 -3692(22)[ZIP_CODE] -3/abstract  
40.  Harrell, Frank. rmsb Package Examples [Internet]. [cited 2020 Nov 6]. Available from: 
https://hbiostat.org/R/rmsb/blrm.html  
41.  Harrell, Frank. General COVID -19 Therapeutics Trial Design [Internet]. [cited 2020 Nov 6]. 
Availa ble from: https://hbiostat.org/proj/covid19/statdesign.html  
42.  Simpson DG, Carroll RJ, Zhou H, Guth DJ. Interval Censoring and Marginal Analysis in 
Ordinal Regression. Journal of Agricultural, Biological, and Environmental Statistics. 1996 
Sep;1(3):354.  
43.  Food and Drug Administration. E9(R1) Statistical Principles for Clinical Trials: Addendum: 
Estimands and Sensitivity Analysis in Clinical Trials [Internet]. 2017. Available from: 
https://www.fda.gov/media/108698/download  
44.  Zhenming S, McCullagh P.  Laplace approximation of high dimensional integrals. Journal of the 
Royal Statistical Society. 1995;57(4):749 –760.  
45.  Doob J. The limiting distributions of certain statistics. The Annals of Mathematical Statistics. 
1935 Sep 1;6(3):160 –169.  
46.  Liu Q,  Shepherd BE, Li C, Harrell FE. Modeling continuous response variables using ordinal 
regression. Stat Med. 2017 Nov 30;36(27):4316 –4335. PMCID: PMC5675816  
47.  Harrell, Frank. Violation of Proportional Odds is Not Fatal | Statistical Thinking [Internet]. [ cited 
2020 Nov 6]. Available from: https://www.fharrell.com/post/po/  
48.  World Health Organization. WHO R&D Blueprint - Novel Coronavirus, COVID -19 Therapeutic 
Trial Synopsis [Internet]. 2020. Available from: https://www.who.int/blueprint/priority -
disease s/key -action/COVID -
19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf  
 
 